

جامعة بابل كلية الطب

دراسة حول تأثير زيت الحبة السوداء على
الاستجابة المناعية للقاح شلل الأطفال

رسالة مقدمة إلى مجلس كلية الطب – جامعة بابل كجزء من
متطلبات نيل

درجة الماجستير في الأحياء المجهرية

من قبل الطالبة

رشا جاسم موسى الورد

الخلاصة

تضمنت الدراسة مائة وسبعة وعشرين (127) طفلاً تتراوح أعمارهم بين يوم واحد و خمسة سنوات. باستخدام فحص التلازن الدموي المنفعل تم قياس المستوى المناعي لهؤلاء الأطفال من خلال علاقتة بالعمر وعدد الجرعة المأخوذة من لقاح شلل الأطفال.

تم اختيار تسعة وسبعين (79) طفلاً عشوائيا لدراسة أثر زيت الحبة السوداء في الاستجابة المناعية للقاح شلل الأطفال ضمن جرعة و فترات زمنية مختلفة. أظهرت النتائج أن هنالك علاقة بين عدد الجرعة المأخوذة من اللقاح والمستوى المناعي لدى الأطفال حيث كان يتراوح بين (1 : 20) للأطفال غير الملقحين و (1 : 40) للأطفال المستلمين جرعة واحدة ليصل إلى (1 : 80) للأطفال المستلمين ثلاث جرعة ليبقى على هذا المستوى مع اختلاف بسيط للجرعة المتقدمة . كما تبين وجود علاقة بين عمر الطفل والمستوى المناعي لديهم إذ أن اوطىء مستوى خلال فترة (الخدج) وأعلى مستوى خلال الثلاث سنوات الأولى من عمر الطفل حيث تراوح بين (1 : 40) و (1 : 320) أما بالنسبة للأعمار الأكبر فأنه يتراوح بين (1 : 40) و (1 : 160) .

ظهر الدور التحفيزي لزيت الحبة السوداء في الاستجابة المناعية للقاح واضحاََ ومرتبطاً مع الجرعة المأخوذة و مدة العلاج وعدد الجرعة المستلمة من اللقاح أيضاً. وباستخدام طريقة التلازن الدموي المنفعل وطريقة الانتشار المناعي المنفرد لحساب المستوى المناعي لدى الأطفال

أظهرت التحليلات الإحصائية (المنوال) النتائج الآتية:

-المستوى المناعي للأطفال الملقحين بجرعة واحدة هو (1 : 40) و (1 : 80) للأطفال الملقحين بجرعتين إلى خمس جرعة .

- المستوى المناعي للأطفال المستلمين زيت الحبة السوداء بجرعة (0.6مل/كغم) لمدة 6 أسابيع كان (1 : 80) و (1 : 160) و (1 : 320) للأطفال الملقحين بجرعة واحدة و بجرعتين وثلاث جرعة فأكثر من اللقاح على التوالي

-المستوى المناعي للأطفال المستلمين زيت الحبة السوداء بجرعة (0.3مل/كغم) لمدة ثلاثة أسابيع كان (1 : 40) للأطفال الملقحين بجرعة واحدة و (1 : 80) للأطفال الملقحين بجرعتين وثلاث جرعة و (1 : 160) للأطفال الملقحين بأربع جرعة أو أكثر .

تم أخيراً دراسة مستوى الكلوبوليبيونات المناعية نوع (ج) للأطفال قبل وبعد إعطائهم زيت الحبة السوداء وكان الاختلاف واضحاً حيث أن المعدل لدى الأطفال قبل إعطائهم الزيت كان (488.325 ملغم/لتر)) وقد تصاعد إلى (986.625 ملغم/لتر)) بعد إعطائهم (0.6 مل/كغم) ولمدة ثلاث أسابيع ومن ثم أصبح (1025.314 ملغم/لتر)) للأطفال المستلمين بعد ست أسابيع من إعطائهم الزيت.

9

بِسْمِ اللّٰهِ الرَّحْمٰنِ الرَّحِیْمِ

﴿وَمَا ذَرَأْتُمْ فِي الْأَرْضِ مُخْتَلِفًا أَلْوَانُهُ إِنَّ فِيَّ

ذَٰلِكَ لَآيَةً لِّقَوْمٍ يَذَّكَّرُونَ﴾

صدق الله العلي العظيم
(الآية ١٣ من سورة النحل)

We certify that this thesis was prepared under our supervision at the University of Babylon as partial requirements for degree of M.Sc. in Microbiology .

supervisor

Dr. Mohammed Aboud AlQarguli

Assistant Professor

supervisor

Dr. Abdul Razzaq AbdulLatif

Assistant Professor

According to available recommendation , I forward this thesis to discussion .

Dr. Mohammad Sabry

Chairman of Department of Microbiology
College of Medicine
University of Babylon

We the examining committee, after reading this thesis and examining the student in its contents , find it adequate as a thesis for the degree of master of Science in Microbiology.

Signature :

**Proffisor Dr. Khairy Abdulla Dawood
Chairman**

Signature:

Assist. prof.Jahfar K. Naama

Signature:

Assist.prof.Yahia A.Shaheed

Member

Member

Approve for the College Committee on Graduate Studies

**Dr. Hussein S. AL-Janabi
Dean
College of Medicine**

Dedication

*To my Parents, my sisters and brothers,
My husband and my best wishes in life :
Yousif and Sama*

ACKNOWLEDGMENTS

I would like to express my sincere gratitude and deep appreciation to my supervisors **Dr.MohammedA.Muhsin and Dr. Abdul –Razzaq A. Latif** for their great help, instructive advice, guidance and support throughout the course of my study.

I am also grateful to Dr. Jafer R. Mohammed and all staff in AL-.Imam-Ali Primary Health Care Center for their great assistance in sample collection. My thanks also go to Dr. Amal M. Hassan for her help and Mr.Hatam Abdul Latif, assistant professor of statistics, in the College of Medicine for his statistical advice.

I am greatly indebted to the children and their families for their great help and co-operation.

Sincere thanks to professor Salih Mahdi Hamid due to languagestic evaluation of the thesis.

Rasha

CONTENTES

Contents	Page No.
ACKNOWLEDGEMENTES	V
Thesis contents	VI
Thesis tables	IX
Thesis figures	X
Abstract	XII
Chapter One \ Introduction	1
Aims of Study	5
Chapter Two \ Literature review	6
History of Poliomyelitis	7
Epidemiology of Poliomyelitis	9
Viral entry spread and neurovirulance	11
Physical and Chemical Characteristic of Poliovirus	13
The nature of immunity against poliomyelitis	13
Response to natural exposure infection	13

The serum and secretary immunity after infection	۱۴
Risk factors	۱۵
Vaccine	۱۷
Development of the Concept of Polio Vaccine	۲۰
<u>Polio vaccines</u>	۲۱
Nigella Sativa	۲۳
Description of Nigella Sativa	۲۴
Chemical Compassion of Nigella Sativa	۲۵
Medical uses of Nigella Sativa oil	۲۸
Nigella Sativa and immune system	۲۹
Properties of Nigella Sativa	۲۹
Chapter Three \ Material & Methods	۳۱
Subjects	۳۲
Data collection formula	۳۵
Oil of Nigella Sativa	۳۶
Blood Samples	۳۶
Equipments and tolls	۳۷
Solution	۳۸
Reagents / Prepared reagents	۳۹
Ready made Reagents	۳۹
Laboratory Investigation / Passive Heamagglutination	۴۰

Inhibition Test	
Single Radial Immunodifusion test	٤١
Statistical Methods	٤٢
Chapter Four \ Results & Discussion	٤٣
Assessment of children immunity against poliomyelitis	٤٤
Evaluation of Nigella Sativa oil effects on specific humoral Immune response against poliovirus in children	٥٠
Assessment of N.S oil effects on total Immunoglobulin-G-	٧٠
Conclusions	٧٢
Recommendations	٧٤
References	٧٥

TABLES

Tables	Page No.
(१) : The biochemical constituents of Nigella sativa.	२६
(२) : Composition of Black Cummin seed Oil Essential Fatty Acids.	२७
(३): Modes of APATs according to number of OPV doses before and after ०.६ ml/Kg /day of N.S oil	०३
(४): Modes of APATs according to number of OPV doses before and after ०.३ ml/Kg /day of N.S oil.	०४
(०): The magnitude of APATs after taken ०.६ ml/kg /day from N.S oil.	६३
(६): The magnitude of APATs after taken ०.३ ml/Kg/day of N.S oil for ३ and ६ weeks duration.	६७
(७) : N.S oil effect on total IgG level.	७१

FIGURES

Figures	Page No.
(1) : The Division of Children.	۳۴
(۲) :The Relation between the Immune Level against Polio Virus and number of OPV Received by Children.	۴۰
(۳): The Modes of APAbTs according to the number of OPV doses .	۴۷
(۴): Immune Level against PolioVirus according to the age (independent on the number of OPV received by the child).	۴۹
(۵): Correlation between number of OPV doses and Modes of APAbTs at ۰.۶ml/kg/day of N.S oil.	۵۰
(۶): Correlation between number of OPV doses and Modes of APAbTs at ۰.۳ml/kg/day of N.S oil.	۶۰
(۷): The magnitude of Immune Response with ۰.۶ ml/Kg /day for six weeks duration of N.S oil treatment.	۶۴

(⁸): The magnitude of Immune Response with 0.7 ml/Kg /day for three weeks duration of N.S oil treatment.	74
(⁹): The magnitude of Immune Response with 0.7 ml/Kg /day of N.S oil regardless the duration.	70
(¹⁰) : The magnitude of Immune Response with 0.5 ml /Kg /day) for six weeks duration of N.S oil treatment.	78
(¹¹) : The magnitude of Immune Response with 0.5 ml /Kg /day for three weeks duration of N.S oil treatment.	78
(¹²) : The magnitude of Immune Response against polio with 0.5 ml /Kg /day of N.S oil regardless the duration.	79

Abbreviations

Ab	Antibody
Abs	Antibodies
Ag	Antigen
APAbTs	Anti Polio Antibody Titers
EPI	Expanded Program Immunization
IPV	Inactivated Polio Vaccine
IR	Immune Response
<i>M</i>	Mode of Antipolio Antibody Titers
<i>Ms</i>	Modes of Antipolio Antibody Titers
MOH	Ministry of Health
N.S oil	Nigella Sativa Oil
NIDs	National Immunization Days
R	Range
VAPP DPT	Vaccine Associated Paralytic Poliomyelitis Diphtheria Tetanus Pertusis.
WHO	World Health Organization

Abstract

One-hundred and twenty seven children between one day and five years of age were included in this study. The pretreated level of anti polio virus antibodies titers (APAbTs) was estimated and evaluated according to the number of oral polio vaccine (OPV) doses received by children as well as their ages. Seventy-nine children were selected to study the effect of N.S oil (which is used in different doses and in different durations) on specific immune response to polio virus. The total immunoglobulin class G (IgG) concentration was studied for the children who took 0.7 ml/Kg /day. A Passive hemagglutination test was found to be a sensitive method for measuring specific anti polivirus antibodies. The immunoglobulins class IgG was, however, determined by using the single radial immunodiffusion test.

The results reveal that there is a clear relationship between the number of OPV doses received by children and the level of APAbTs. This titers increases gradually from 1:20 for unvaccinated children to 1:40 for the children who had one OPV dose and 1:80 for those who had three OPV doses and remained stable at this level with slight variability for further doses. There is some correlation between the age of children and APAbTs: the lowest level is during neonatal period, and the range of APAbTs during the first three years (apart from

neonatal period) is from 1:40 to 1:320, whereas for older age it is 1:40 to 1:160.

The role of N.S oil on specific IR to polio appears to be an inducer and exhibits an enhancing effect on APAbTs. In addition to its magnitude this enhancing effect correlates with the dose of N.S oil, duration of treatment, and the number of OPV doses received by children before treatment. The Modes to APAbTs (\mathcal{M}) in the pretreatment condition or the untreated children are 1:40 for the children who had one OPV dose, and 1:80 for those who had two or more OPV doses. For the children treated by 0.6 ml/kg / day of N.S oil for 6 weeks, the \mathcal{M} is 1:80, 1:160, and it is 1:320 for those who had one, two, three and four (or more) OPV doses respectively. The \mathcal{M} in children treated with 0.3 ml/kg / day for three weeks is 1:40 for those who had one OPV dose, 1:80 for those who had two or three OPV doses, and 1:160 for those who had four (or more) OPV doses.

The stimulation effect of N.S oil on total IgG for children before and after treatment with N.S oil has been studied. It correlates with the duration of treatment, where the mean of total IgG is 488.320 mgdl before treatment, and 986.620 and 1020.314 mgdl for children treated by 0.6 ml/kg / day for three and six weeks respectively.

جامعة بابل كلية الطب

دراسة حول تأثير زيت الحبة السوداء على
الاستجابة المناعية للقاح شلل الأطفال

رسالة مقدمة إلى مجلس كلية الطب – جامعة بابل كجزء من
متطلبات نيل

درجة الماجستير في الأحياء المجهرية

من قبل الطالبة

رشا جاسم موسى الورد

الخلاصة

تضمنت الدراسة مائة وسبعة وعشرين (١٢٧) طفلاً تتراوح أعمارهم بين يوم واحد و خمسة سنوات. باستخدام فحص التلازن الدموي المنفعل تم قياس المستوى المناعي لهؤلاء الأطفال من خلال علاقة بالعمر وعدد الجرعة المأخوذة من لقاح شلل الأطفال.

تم اختيار تسعة وسبعين (٧٩) طفلاً عشوائياً لدراسة أثر زيت الحبة السوداء في الاستجابة المناعية للقاح شلل الأطفال ضمن جرعة و فترات زمنية مختلفة. أظهرت النتائج أن هنالك علاقة بين عدد الجرعة المأخوذة من اللقاح والمستوى المناعي لدى الأطفال حيث كان يتراوح بين (١ : ٢٠) للأطفال غير الملقحين و (١ : ٤٠) للأطفال المستلمين جرعة واحدة ليصل إلى (١ : ٨٠) للأطفال المستلمين ثلاث جرعة ليبقى على هذا المستوى مع اختلاف بسيط للجرعة المتقدمة . كما تبين وجود علاقة بين عمر الطفل والمستوى المناعي لديهم إذ أن اوطىء مستوى خلال فترة (الخدج) وأعلى مستوى خلال الثلاث سنوات الأولى من عمر الطفل حيث تراوح بين (١ : ٤٠) و (١ : ٣٢٠) أما بالنسبة للأعمار الأكبر فأنه يتراوح بين (١ : ٤٠) و (١ : ١٦٠) .

ظهر الدور التحفيزي لزيت الحبة السوداء في الاستجابة المناعية للقاح واضحاً ومرتبطاً مع الجرعة المأخوذة و مدة العلاج وعدد الجرعة المستلمة من اللقاح أيضاً. وباستخدام طريقة التلازن الدموي المنفعل وطريقة الانتشار المناعي المنفرد لحساب المستوى المناعي لدى الأطفال

أظهرت التحليلات الإحصائية (المنوال) النتائج الآتية:

-المستوى المناعي للأطفال الملقحين بجرعة واحدة هو (١ : ٤٠) و (١ : ٨٠) للأطفال الملقحين بجرعتين إلى خمس جرعة .

- المستوى المناعي للأطفال المستلمين زيت الحبة السوداء بجرعة (٠.٦ مل/كغم) لمدة ٦ أسابيع كان (١ : ٨٠) و (١ : ١٦٠) و (١ : ٣٢٠) للأطفال الملقحين بجرعة واحدة و بجرعتين وثلاث جرعة فأكثر من اللقاح على التوالي

-المستوى المناعي للأطفال المستلمين زيت الحبة السوداء بجرعة (٠.٣ مل/كغم) لمدة ثلاثة أسابيع كان (١ : ٤٠) للأطفال الملقحين بجرعة واحدة و (١ : ٨٠) للأطفال الملقحين بجرعتين وثلاث جرعة و (١ : ١٦٠) للأطفال الملقحين بأربع جرعة أو أكثر .

تم أخيراً دراسة مستوى الكلوبيولينات المناعية نوع (ج) للأطفال قبل وبعد إعطائهم زيت الحبة السوداء وكان الاختلاف واضحاً حيث أن المعدل لدى الأطفال قبل إعطائهم الزيت كان (٤٨٨.٣٢٥ ملغم/لتر)) وقد تصاعد إلى (٩٨٦.٦٢٥ ملغم/لتر)) بعد إعطائهم (٠.٦ مل/كغم) ولمدة ثلاث أسابيع ومن ثم أصبح (١٠٢٥.٣١٤ ملغم/لتر)) للأطفال المستلمين بعد ست أسابيع من إعطائهم الزيت.

CHAPTER ONE

INTRODUCTION

CHAPTER ONE

INTRODUCTION

A great variety of infectious microbes such as virus, bacteria, fungi, protozoa and parasites are found in our environment. In normal individuals, most of these microbes are short living and of little morbidity and mortality, except in few situations, this is due to the immune system which combats infectious agents in many different forms . A wide variety of immune responses are required to deal with each type of infection (Roitt *et.al.*, 2001) .

Man is supplied with all capabilities of defense mechanisms. Innate immunity is the first line of defense followed by the specific immune response.

Following exposure to an antigen (Ag), the development of specifically altered reactivity is called the immune response (IR). It is triggered when the Ag enters the body and encounters specialized cells, called the Antigen Presenting Cells(APC). Then complexes and intricately regulated sequences of events involve several cell types. (Hyde, 2000 ; Parslow , 2001). The (IR) involves two phases: the Recognition Phase and the effector phase. During the Recognition Phase, Ag activates specific cells that recognize it, whereas in the Effector Phase the lymphocytes coordinate with an IR that eliminates the source of Ag, and this is achieved by clonal selection (Roitt and

Rabson, 2000 ; Paraslow, 2001). The Recognition Phase involves the recognition of the Ag by particular lymphocytes. B-cells usually recognize intact Ag molecule, where Tcells recognizes Ag fragments on the surface of other cells. The recognition leads to the clonal expansion and differentiation of the effector and memory cells (Brooks *et.al.*, 1998; Roitt and Rabson, 2000). The IR has at least four major functional properties : these are (Hyde, 2000) :

A-Self-nonsel discrimination : It responds to foreign micro-organisms and even to cells and tissues from other hosts but not the constituents that make up the host body.

B-Specificity : It is the ability to detect subtle difference target epitopes, and to respond to each of these individually.

C-Memory: It is the capacity of the immune system to provoke more rapid and more vigorous responses in the subsequent encounters than those occurring at the inial encounter.

D-Adaptiveness : It is the ability to respond to previously unrecognized Ags.

Many different ways were used to enhance or help immune system to control and cure from infectious agents i.e.; (herbal plant, vaccines, antibiotics, immunoglobulin) .

It has been reported that *Nigella sativa* (N.S) is an important herbal plant to cure many of the common sicknesses. Reported the Black Seed is important to heal many illnesses except death (Al-Rawi, 1988). The reason might be due to the complexes of

the chemical structure of the N.S;which is reported to have over one hundred different chemical constituents in addition to sources of the essential fatty acids. Thus, the oil of N.S is used medically in many aspects including the enhancement of the IR. (Meral *et.al.*, ۲۰۰۰ ; Cindy, ۲۰۰۰) .

Poliomyelitis disease is caused by a dangerous virus , that has received considerable attention all over the such World Health Organization (WHO) and all countries. Oral polio vaccine (OPV) induce humeral immunity and also systemic immunity, particularly inside the intestine (Ghendon and Robertson , ۱۹۹۴). So, an important program vaccination scheme has been adopted and implemented, and is still continuous to control the disease .

Aims of Study

- Estimation of anti polio antibody titers (APAbTs) and evaluate for both response to poliovirus vaccine and poliovirus vaccination programs.
- Study the effect of N.S. oil on specific humoral immunity to poliovirus in vivo.
- Estimation the best dose of N.S oil and duration of treatment for reaching a protective level of immunity.

CHAPTER TWO

LITERATURE REVIEW

CHAPTER TWO

LITERATURE REVIEW

2.1. History of Poliomyelitis

The disease of poliomyelitis has a long history. The first example may even have been more than 3000 years. Two Egyptian mummies showed limp deformities characteristic of poliomyelitis. The first one was 3700 B.C and the second 1209 B.C (Melnick, 1984; Robbins, 1986). In 1209 B.C, Mummy Giptah was found with an equines foot, and the priest Ruma with a withered leg and equines foot, shown on a plaque and probably poliomyelitis in 1080-1300 B.C (Grist and bell, 1984; Stanely and Walter, 1999). In 1009 a painting by Pieter Bruegel shows a crippled beggar, not necessarily polio although it did probably occur during that period in England (Sabin, 1981). In the eighteenth century the first description of poliomyelitis was given by Underwood; while in the nineteenth century the first epidemic of poliomyelitis occurred in Island of St.Helena. (Thomas, 1984; Samuel *et.al.*, 1998).

Hein was the first who described some scattered sporadic cases in 1840 and noted apparently major epidemic in 44 cases in Stockholm during the summer of

1887. The first description of the pathological processes in poliomyelitis with the involvement of the anterior horn cells of the spinal cord was given by Duchene in 1800 (Samule *et.al.*, 1998; Stanely and walter, 1999). The first major polio epidemic reported in the United States occurred in Vermont during the summer of 1893. It consisted of 132 total cases, including some adults (Melnick, 1984; Robines, 1986). Not until 1908 was the actual polio virus identified by two Austrian physicians, Karl Land Steiner and Popper by experiment producing paralytic disease in monkeys by spinal cord inoculation of brain tissue from fetal cases (Samuel *et.al.*, 1998) (Stanely and waltar, 1999). In 1909, the passage of the virus through a monkey was experimented by Flexner and, the year 1916 saw a large outbreak of polio in the United States. The total number of affected individuals was unknown; over 9000 cases were reported in New York City alone (Melnick, 1984; Robines, 1984). In the 1930s Paul and Track recovered the virus in feces of both patients and healthy carriers repeatedly over a period of weeks and the concept of poliomyelitis as an enteric infection became established. In 1948, Bodian established that three closely related but antigenically distinct virus strain could cause poliomyelitis. These viruses which are designated polio virus types 1, 2, 3 are classified as picorna viruses which belong to the enterovirus group (Melnick, 1990). The growth of the virus on tissue cultures happened in 1949

(Stanley and Walter, 1999; Melnick, 1990), the first large scale trial of Salk (dead vaccine) by injection, did in 1954 and eventually the first general use of sabin (live attenuated vaccine) by mouth in 1958 (Stanley and Walter, 1999).

2.1.2. Epidemiology of Poliomyelitis

Poliomyelitis is an acute viral infection which ranges in severity from a non-specific illness to paralysis with permanent disability. Polioviruses have become established throughout most of the world's population and survival for many centuries in an endemic fashion, reaching almost all infants very early in life. Passive immunity is transferred from mother to offspring and many infants subsequently experienced their first poliovirus infection during the first few months of life while maternal antibodies still provide protection. Furthermore, because such large proportion of poliovirus infection take an inapparent or sub clinical form, the paralytic cases that occur could go unnoted in population faced with very high infant and child mortality rates (Christie, 1987 ; Streble , 1992 ; Melnick, 1990). Poliomyelitis has had three epidemiologic phases: endemic, epidemic and vaccine era. The first two reflect prevaccine patterns, and the generally accepted explanation is that improved systems of hygiene and sanitation in cooler climates promote the transition from endemic to epidemic paralytic disease in those societies (Minor , 1996 ; Jawtez, 1998;

Stanely and Walter, 1999). Most infections with poliovirus are asymptomatic and less than 1% result in paralysis. Paralysis rates are highest with poliovirus type 1 (the most frequent cause of epidemics and may be less than 1 case per 1000 infections with type 3). A syndrome identical with polio is caused by other enteroviruses notably enterovirus 71, and some atypical cases may be difficult to differentiate clinically from Guillian Bare syndrome (Jawetz , 1998; Munsat, 1991).

Symptomatic cases are typically characterized by two phases. The first, a non specific febrile illness followed (in a small percentage of cases) by aseptic meningitis and/or paralytic disease. Depending on the site of paralysis, poliomyelitis can be classified as a spinal, bulbar or spin bulbar disease. Case fatality is variable. It is highest in the oldest patients and may reach 5-10%. The disease is transmitted from person to person primarily by direct fecal oral contact. However, the virus can also be transmitted by indirect contact with infectious saliva or feces, or by contaminated sewage or water (Gromeir and Wimmer, 1998; WHO, 1999).

Viruses can be recovered from the pharynx and intestine of patients and healthy carrier, the prevalence of infections is highest among household contacts when the first case is recognized in a family, all susceptible in the family are already infected (Jawetz , 1998). There is no evidence of a persistent wild poliovirus carrier state or animal or insect reservoir and the

virus can survive only for finite periods of time in the environment.(Streble et.al., 1992).

Higher non-human primates (chimpanzees and gorillas) are susceptible to infection and disease but these populations are not sufficiently large to sustain polio virus transmission in the absence of human infection. Humans are the only natural reservoir of poliovirus; therefore, once poliovirus is deprived of its human host through immunization, it will rapidly die out (Dowdle, 1997 ; WHO, 1999).

Poliovirus in sewage reflects the prevalence of infection in the community; contamination of surface water may occur through discharge of untreated or inadequately treated sewage or run off from contaminated soil (WHO, 1988).

2.1.3. Viral Entry, Spread and Neurovirulence

Poliovirus enters the body through the mouth and implants itself in the mucosa of the throat (when large numbers are ingested) and in the intestine (Faden *et.al.*, 1993). The virus multiplies in the intestinal epithelium or within the collection of the lymphoid tissue known as Peyer's patches (Onorato *et.al.*, 1991; Arie *et.al.*, 2000). Newly synthesized virus is released into the intestinal lumen and make its way to local lymph nodes. It can be detected very soon after infective virus, then it reaches the systemic lymph nodes and the blood stream producing a primary viremia(WHO, 1988 ; Onorato *et.al.*, 1991).

The appearance of the virus in the blood coincides with the period of what is called the 'minor illness'; non specific syndrome which occurs in the majority of infection and subsides in 1-2 days (Racaniello, 1998). Maintenance of persisting viremia is required for the viral invasion of the central nervous system, a rare event that occurs in approximately 1-2% of all infections and the ability of the poliovirus to infect certain types of virus-binding activity in these tissues such as brain spinal cord and intestine (Modlen *et.al.*, 1997 ;Munsat , 1991 ;Melnick, 1990). In Central Nervous System (CNS) poliovirus replicates mainly in the motor neurons in the anterior horn of the spinal cord, in the brain stem and in the motor cortex. Paralysis results when viral replication destroys sufficiently large number of motor neurons in region of the central nervous system that controls specific muscles(Arie *et.al.*, 2000). Neurovirulence in the general refers to the ability of poliovirus to replicate in, and destroy cells of, the central nervous system(Melnick , 1990). Both naturally occurring polioviruses and variants isolated in the laboratory display a wide range of neurovirulence as determined by the inoculation of different experimental animals by different routes (Jublett *et.al.*, 1980 ; Racaniello 1988 ;Racaniello , 1992 ;Modlen *et.al.*, 1997).

2.1.4. Physical and Chemical Characteristics of Poliovirus

Poliovirus is stable at acid pH and can survive for weeks at room temperature and for many months at zero to 4°C (WHO, 1999). As with other enteroviruses, poliovirus is resistance to ether, 70% alcohol and other laboratory disinfectants. Treatment with 0.3% formaldehyde, or free residual chlorine at a level of 0.3 to 0.5 parts per million rapidly inactivates poliovirus, as does exposure to a temperature of 60°C or higher and to ultraviolet (Minor and Bell, 1990).

2.1.5. The Nature of Immunity against Poliomyelitis

A- Response to natural infection : Following natural exposure, IgM appears in the serum about 4-10 days after infection. The IgM Response is 2-8 fold and level peaks at greater than IgG response about two week after exposure, and disappears from the serum within 10 days. Immunoglobulin G (IgG) level increases steadily starting from two weeks after infection and persisting in the body for months to years . IgA antibody appears in the serum two to six weeks after exposure, remains at low levels, and persist for years (EPI, 1993 ;Samuel *et.al.*, 1999). Serum antibodies are type-specific. There may be low degrees of heterotypic antibody induced infection especially between type 1 and type 2 polioviruses (Stanly and Walter , 1999). It is believed that serum

neutralization antibodies (primary IgG) persist for life (Ogra, 1984; EPI, 1993). Passive immunity is transferred from mother to fetus via the placenta (Onorato *et.al.*, 1988; Ananthakrishnan *et.al.*, 1988). Poliovirus infection also induces development of secretory IgA antibody (Ogra, 1984; Ramsay *et.al.*, 1994; Fortran *et.al.*, 1990).

B-The serum and secretory immunity after natural infection.

a.Duration of serum antibody: After natural infection with poliovirus, serum IgG antibodies persist for many years. For example, in an isolated Eskimo population, IgG persists for at least 20 years after natural infection in the absence of any further exposure to poliovirus (Orenstein *et.al.*, 1988).

b.Duration of immunological reaction in the intestine: The persistence of local intestinal IgA can be analyzed by studying intestinal resistance to infection with polioviruses. It was suggested that a decrease in serum antibody titer could be a good indicator of reduction in intestinal local immunity. (Ghendon and Robertson, 1994).

c.Duration of local immunity in the nasopharynx: Secretory IgA antibody has been detected in the nasopharyngeal secretion of individuals 10-15 years after natural infection. (Ogra, 1984; Fortuin *et.al.*, 1990).

C-Risk factors:

A number of factors may affect the potential for infection with poliovirus or the severity of clinical poliomyelitis.

a.Immunodeficiency

Persons with congenital and acquired B-cell immunodeficiency have markedly increased risk of (OPV) vaccine associated with paralytic poliomyelitis (VAPP). Approximately 29% of the 89 VAPP cases reported to occur between 1980 and 1997 are immunodeficient. Two thirds of immunodeficient VAPP cases have occurred among infant OPV recipients and the remaining immunodeficient patients who are mostly adults have acquired VAPP via exposure to infants recently fed OPV. The risk of VAPP among newborn infants with a congenital B-cell immunodeficiency disorder is estimated to be 2000 higher than for an immunocompetent infant (Vernon *et.al.*, 1990; Streble *et.al.*, 1992; WHO, 1992).

b.Injection

it has been shown that administration of multiple intramuscular injection during the incubation period of wild poliovirus increases the risk of paralytic disease more than ten folds (Streble *et.al.*, 1994). Cases of DPT injection associated paralysis are usually reported in children six months of age or older, reflecting the fact that most infants are protected from

poliomyelitis during the first few months of life by maternal antibodies. Therefore, it is desirable to complete a primary series of OPV/DPT immunization by 4 months of age during which time the risk of post-injection poliomyelitis is extremely low (Sutter *et. al.*, 1992).

c. Physical activity:

Early studies show that for persons who develop paralytic poliomyelitis, the intensity of physical activity in the first 48 hours after the onset of paralysis correlated with the severity of paralysis. In contrast, physical activity prior to the onset of paralysis does not relate to subsequent paralysis (Sabin, 1980).

d. Pregnancy, age and sex:

poliovirus infections occur equally in male and female although paralysis is more common in boys (Ryder *et.al.*, 1993). Among adults, women are at greater risk of infection but are not necessarily at a greater risk of paralysis. Clinical data suggest that both the incidence and the severity of poliomyelitis may increase in pregnant women (Harjulehto *et.al.*, 1989, Harjulehto *et.al.*, 1993).

e. Tonsillectomy

Persons with tonsillectomies have a more risk than those with intact tonsils. Later studies indicated that previous tonsillectomy at any time increased the risk of bulbar

poliomyelitis compared with children who had intact tonsils , seronegative children who had their tonsils removed had a lower level of secretory antibody response in the pharynx when immunized with OPV (Ogra and Karzon 1971; Patriarca *et.al.*, 1997).

2.1.6. Vaccine:

Immunization is the process of inducing immunity artificially by either vaccination (active immunization) or administration of antibodies (passive immunization). (Behrman *et.al.*, 2000, 2004).

Vaccination is the administration of any vaccine or toxoid (inactivated toxin) for preventing disease. The first vaccine was named after Vaccinia, the cow pox virus. Jenner pioneered its use two hundred years ago and it was considered the first scientific attempt to prevent an infectious disease (small pox) (Behrman *et.al.*, 2000, Roitt *et.al.*, 2001). The work of Pasteur emerged one hundred years later when the general principle governing vaccination was known and altered preparation of microbes used to generate enhanced immunity against virulent organisms (Roitt *et.al.*, 2001; Geison, 1990). With Brunet's clonal selection theory (1907) and the discovery of B and T lymphocyte, the key mechanism became clear and the antigens of a vaccine must induce clonal expansion in specific T or B cells leaving behind a population of memory cells (Bottiger, 1984; Linder, 1994; Roitt *et.al.*, 2001). The principle of

vaccination is based on two key elements of adaptive immunity, namely specificity and memory. The memory cells allow the immune system to mount a much stronger response on a second encounter with antigen, and this secondary response is both faster to appear, usually within four to five days and more effective than the primary immune response (Sabin, 1980; Roitt, *et al.*, 2001; Behrman, *et al.*, 2004). The response to vaccine in clinical practice is assessed by the serum concentration of specific antibodies. The presence of antibodies usually correlates with protection. (Behrman *et al.*, 2004, 2004). The art of vaccination to produce antigenic preparations from the pathogen depend on the fact that

- a. It is safe to administer.
- b. It induces the right sort of immunity.
- c. It is affordable by the population at which they are aimed (Linder *et al.*, 1994; Roitt *et al.*, 2001).

The type of antigens used in a vaccine depends on many factors. The more antigens of the microbe retained in vaccine, the better. Live vaccine can be natural or attenuated organisms. It is a part from vaccinia; no other completely natural organism has ever come into standard use. Like bovine and simian, rota virus has been tried in children, and in the Middle East and Russia, Leishmania infection from mild cases is reputed to induce immunity (Adim, 1980; Roitt *et al.*, 2001) but the attenuation (changes) of micro-organisms makes them less able

to grow and cause disease in their natural host. Galmette and Guerin were the first who successfully done with a bovine strain of *Mycobacterium tuberculosis*, which during 13 years (1908-1921) of culture in vitro, changed into much lesser virulent form currently known as BCG (Bacilli Calmette – Gurine) that has at least protective effects against TB. The real successes with virus vaccine started with the [17D] strain of yellow fever virus obtained by passage in mice and chicken embryos (1937); this was followed by similar approach with polio, measles, mumps and rubella (Fulginiti, 1980; Roitt *et.al.*, 2001). Killed vaccines are intact but non living organisms like virus vaccines (polio, rabies, influenza, hepatitis -A-) and bacterial vaccine (pertussis, typhoid, cholera, plague, Q fever). Inactivated toxins and toxoids are the most successful of all bacterial vaccines (Linder *et.al.*, 1994).

In the 1920s, during work on the production of animal sera for human therapy, it was discovered that certain substances (aluminum salts) added to, or emulsified with, an antigen to enhance antibody production act as adjuvant. Aluminum hydroxide is still widely used with diphtheria and tetanus toxoids (Roitt *et.al.*, 2001). In addition, an adjuvant must be safe, stable and affordable and should target particular cells of the immune system with reasonable specificity (Funkhous *et.al.*, 1987; Lieberman *et.al.*, 1990).

In technological developments it is apparent that the number of general strategies for making new vaccines is rapidly expanding such that all antigens or epitopes can be presented in a highly immunogenic form in the context of a live or non live vaccine (Rechman *et.al.*, 1988). Protein antigens alternatively can be expressed through a DNA-based vaccine. Further understanding of gene function in viral and bacterial pathogens should enable live vaccines to be more stably and predictably attenuated as vaccines and as live vectors for immunization against pathogens (Williams *et.al.*, 1991; Darji *et.al.*, 1997). Adjuvant technologies should advance to the point at which formulations that are more potent than aluminum salts to gain a wide spread should use killed vaccines and an oral delivery of purified proteins to become feasible for immunization (Wessels *et.al.*, 1990; Darji *et.al.*, 1997).

2.1.7. Development of the Concept of Polio Vaccine

Attenuated viruses may be isolated by the passage of the virus in different animal hosts or in various cultured cells, or in a combination of both (Sabin, 1980).

Flexner and Amoss in the 1920s were the first who suggested the concept of using such “weakened” polio virus to immunize against poliomyelitis (Racaniello, 1988). The first use of the term “attenuated” in connection with polio virus vaccine is attributed to Kolmer who has believed that extensive passage

of the strain of poliovirus in monkeys [MV] produces a virus “of greatly reduced infectivity for human being” (Sutter, 1990).

Theiler (1941) was the first who truly isolated polio virus strain after 100 passages in mice. The P₂/Lansing strain of polio virus no longer caused paralysis after intracerebral inoculation of rhesus monkeys (Morens *et.al.*, 1991). The early mouse-passage P₂/Lansing virus induced paralysis in monkeys at high rate then subsequently Enders and his colleagues showed that the growth of the P₁/Brunhild strain of poliovirus in cultured human non-neural tissues produced a virus with reduced neurovirulence in monkeys (Dalakas *et.al.*, 1984). The passage of type 2 strain of poliovirus in rodents produces a strain which when administered orally to humans induces an immune response in the absence of the disease (Murdin *et.al.*, 1992).

2.1.8. Poliovaccines

Two different kinds of polio vaccines are available. A live attenuated oral polio vaccine (OPV) developed by Albert Sabin in 1961 and an inactivated killed injectable polio vaccine (IPV) originally developed in 1900 by Jones (EPI, 1997; Stanely and walter, 1999). The two vaccines are highly effective against all three types of poliovirus, but there are significant differences in the way each vaccine works (WHO, 1996).

Inactivated polio vaccine (IPV) works by producing protective antibodies in the blood, thus preventing the spread

of poliovirus to the CNS (Behrman,*et.al.*, 2000). The inactivated polio vaccine provides only very low level of immunity to poliovirus inside the gut (EPI, 1990); therefore, the inactivated polio vaccine provides an individual protection against polio paralysis but only marginally reduces the spread of wild poliovirus in a person immunized with IPV because the virus multiplies inside the intestine and is shed in stools (Evans, 1982; WHO, 1996; Hinman, *et.al.*, 1987). Consequently, the IPV can not be used to eradicate polio, let alone its cost which is over five times then that of OPV. The cost includes that of needles and syringes as well as the need for trained health workers to administer the vaccine using sterile injection procedures (Salk, 1982; Beale, 1990; Behrman,*et.al.*, 2000).

The advantage of the IPV is that it does not carry the risk of paralysis associated with OPV (WHO, 1997). OPV limits the multiplication of wild (natural occurring) virus inside the gut (Behrman,*et.al.*, 2000; Jawetz, 1998). This vaccine works by inducing not only humeral immunity but also mucosal immunity particularly inside the intestine. This vaccine therefore, produces good barrier against circulation of virus and creates passive immunity to close contacts by means of shedding of vaccine virus in the stools of recently immunized children (Salk, 1982; Behrman *et.al.*, 2002). Another advantage is that it is relatively

۲.۲. Nigella Sativa

The plant is also called Black Seed, Black Cumin, Nigella Sativa, Kalonji, Schwarz Cummel, Sinonj Nutmeg flower, Black Caraway, Habba Sowda, Fennel Flower (AL- Rawi, ۱۹۸۸; EL-Hazmi *et.al.*, ۱۹۹۲) .It is indigenous to the Mediterranean region(AL-Rawi, ۱۹۸۸). In Iraq, it is distributed in Mosul, Erbil, Kirkuk, Sulaimaniya as well as south Jazira (AL-Rawi, ۱۹۸۸). It is a herbaceous plant and originates from the common fennel flower plant (Cindy, ۲۰۰۰). N.S is sometimes mistakenly confused with the fennel herb plant [Foeniculum Vulgare] (EI-Feki *et.al.*, ۱۹۹۷). The black seed is a plant which has been used widely as a folk treatment for about ۲۰۰۰ years(EI-Tahir *et.al.*, ۱۹۹۳). In the Prophet Tradition, it is written that the N.S oil prevents and, indeed heals all illnesses except death itself (AL-Rawi, ۱۹۸۸).In the Easton's Bible dictionary it is clarified that the Hebrew word for black cumin, "Ketsah",undoubtealy refers to the N.S, a small annual of the order Ranunculaceae which grows widely in the Mediterranean countries and is cultivated in Egypt and Syria for its seed (EI-Kadi and Kandil , ۲۰۰۴) N.S was discovered in Tutankhamen's tomb implying that it played an important role in ancient Egyptian practices(Sanamin ۲۰۰۴), whereas the famous Greek physicians used black cumin seed to treat headaches, toothaches, nasal congestion and intestinal worms. They are also used as a diuretic to promote menstruation

and increase milk production(Shamis AI-Deen ,١٩٩٠ ; Morsi ,٢٠٠٠).

٢.٢.١. Description of Nigella Sativa:

It is an aromatic plant from the Ranunculaceae family. This family includes many kinds which vary in shapes and chemical structure. Among the list the most important kinds are:

a. The common Nigella Sativa: This kind has a fast and strong growth with an average height of ٦٠ cm. It also has heavy ramification. The leaves are divided into small parts of filamentary shape. Roses are white mixed with blue colour. The seeds have aromatic smell. (El-Hazmi *et.al.*, ١٩٩٢).

b. The Damascus Nigella Sativa: This resembles the first kind but differs in the shape of leaves, which are divided into very long and thin parts. The roses are big and blue in color (El-Hazmi *et.al.*, ١٩٩٢).

c. The Eastern Nigella Sativa: This kind is characterized by its weak growth it's length is no more than ٤٠ cms. The roses are yellow with red spots. (El-Hazmi *et.al.*, ١٩٩٢).

2.2.2. Chemical Composition of Nigella Sativa :

Black Seed contains about 100 valuable nutrients (Ali, 1997). It contains about 12% protein, 38% carbohydrates and 30% plant fat and oils (Hammed *et.al.*, 2002; AI –Kaisey *et.al.*, 2002) and also contains vitamin B₁, B₂, niacin and vitamin C (Shamis AI-Deen, 1990). The active ingredients of Black Seed (Thymoquinone Nigellon) and Black Seed oil is 30% more concentrated than the raw seed and they are rich in polyunsaturated fatty acid known as essential fatty acid (AI –Kaisey, 2002).

Table (1) : The Biochemical Constituents of Nigella Sativa Arranged in an alphabetical Order (Haq *et.al.*, 1990; Ali, 1997; Ghosheh *et.al.*, 1999).

١	Alanine	٢٤	Lysine
٢	Ametole	٢٥	Magnesium
٣	Arginine	٢٦	Methionone
٤	Ascorbic acid	٢٧	Myristic acid
٥	Asparagines	٢٨	Nigellin
٦	Calcium	٢٩	Nigellon
٧	Campsterole	٣٠	Oleic acid
٨	Carvine	٣١	Palmitic acid
٩	Cymene	٣٢	Phenyl alanine
١٠	Cystine	٣٣	Phytostorols
١١	Dehydroascorbic acid	٣٤	Potassium
١٢	Eicosadienoic acid	٣٥	Beta sitosterol
١٣	Glucose	٣٦	Alpha spinasterol
١٤	Glutamic	٣٧	Sodium
١٥	Glycine	٣٨	Stearic acid
١٦	Iron	٣٩	Stigma sterol
١٧	Isoleucine	٤٠	Tann
١٨	Kaempferol	٤١	Threonine
١٩	Leucine	٤٢	Thymohydroquinine
٢٠	d-limonene	٤٣	Thymoquinone
٢١	Linoleic acid	٤٤	Tryptophan
٢٢	Linolenic acid	٤٥	Tyrosine
٢٣	Lipase	٤٦	Zinc

**Table (٢) : Composition of Black Cummin Seed Oil
Essential Fatty Acids (EFAs)(Al –Rawi ,١٩٨٨).**

Essential Fatty Acids (EFAs)	%
Myristic acid	0.5%
Palmitic acid	13.7%
Palmitic acid	0.1%
Stearic acid	2.6%
Oleic acid	23.7%
Linolenic acid (omega-6)	57.9%
Linolenic acid (omega-3)	0.2%
Arachidonic acid	1.3%

2.2.3. Medical Uses of N.S Oil

The Oil of N.S is used in different folk treatments: burns, acne, skin rash, falling hair, asthma, aches and pain. It also

regulates blood sugar level, health supplement and blood cholesterol (Shamis AI –Deen, ۱۹۹۰; Sanamin, ۲۰۰۴) .In addition, the oil of N.S is used in the treatment of liver diseases, gall bladder problems as well as heart(EL-Tahir *et.al.*, ۱۹۹۳). This oil is also used for treating immune disorders; it also has antimicrobial activities: the gram positive bacteria represented by *Staphylococcus aureus*, gram negative bacteria represented by *Pseudomonas aeruoginosa*, *Escherischia coli* and pathogenic yeast *Candida albicans* (Hanafy, ۱۹۹۱; Baqir *et.al.*, ۲۰۰۲). The oil is used as anti-tumor and the active ingredients are thymoquinone and dithymoquinone both of which inhibit tumor cell in vitro experiments even tumor cells resistance to anti-cancer drug (Worthen *et.al.*, ۱۹۹۸). Recent studies show that when the oil of N.S is incubated with cancer cell, it cannot produce fibroblast growth factor and the protein colleagues, both necessary for blood vessel growth in the tumor (Worthen *et.al.*, ۱۹۹۸; Baqir *et.al.*, ۲۰۰۲); without blood supply tumor cannot grow.

۲.۲.۴. Nigella Sativa and Immune System

N.S oil has been used in many countries of the Middle and Far East as a natural treatment for more than ۲۰۰۰ years. There are many Traditions that have mentioned this seed for more than ۱۴۰۰ years(EI –Kadi and Qandil ,۲۰۰۴). The role of the N.S in natural immunity was not estimated until ۱۹۸۶ (Sanamin ,۲۰۰۴). N.S oil enhances both the immunity system of the body and improves its function (Cindy, ۲۰۰۰). N.S oil has been mentioned to stimulate the immune system when the T-cells treated with Nigella Seed protein produce greater amount of cytokines, specifically interleukin-۱ beta and tumor necrosis factor (Haq-A *et.al.*, ۱۹۹۰, ۱۹۹۹). It has been also mentioned that it supports increased production on immune cells, bone marrow cells and B-cells that produce antibodies and stimulated neutrophil activity (Sanamin, ۲۰۰۴). N.S oil has been found to provide children with all the energy required for the active stage of life, and the regular use of N.S oil increases the strengthening of immune system as well as acts as a antiviral effect (Salim and Hossian, ,۲۰۰۰;Burtis and Bucar,۲۰۰۰).

۲. ۲.۰. Properties of Nigella Sativa Oil :

a. calcium antagonist activity

It has been shown in vitro that the volatile oil of N.S inhibits intestinal and tracheal smooth muscle contractions. This effect is attributed to the calcium antagonist activity of Nigella oil (Aqel, ۱۹۹۲). This observation is further supported by other

studies which show that thymoquinone and dithymoquinone (active ingredients of N.S) inhibit the release of histamine from rat peritoneal mast cells, through a mechanism which involves the entry of calcium ions (Chakravarty, 1993). It seems likely that the observed bronchodilatation action or the antihypertensive effects of N.S oil reported in vivo could in part be explained by the calcium antagonist activity of N.S (El-Tahir *et.al.*, 1993; Gilani, 2001).

b. anti-oxidant activity

The essential oil of N.S seeds has an anti-oxidant activity (Meral *et.al.*, 2001). Such activity is attributed to thymoquinone, carvacrol and t-anethol consistent of the oil (Burits and Bucar, 2000). Furthermore, thymoquinone has been shown to have free radical scavenging activity, and through this mechanism it inhibits benopyrene-induced for stomach carcinogenesis in mice (Badary *et.al.*, 1999).

CHAPTER THREE

MATERIALS & METHODS

CHAPTER THREE

MATERIALS AND METHODS

3.1. Subjects :

This study which covers the period from October 2002 to August 2004, includes One hundred and twenty Seven (127) children whose ages between one day and five years. For all of them, estimations of APATs. according to number of oral polio vaccine doses received have been done, as well as according to their ages.

Seventy-nine (79) children were studied to evaluate the effect of N.S oil on specific immune response to polio virus . On a random selection basis, they were divided into two major groups, forty- one (41) children were assigned in the first major group and thirty- eight (38) children were in the second. The children within the first major group were subjected to treatment at 0.6 ml/kg / day in two divided doses. However, they were subdivided according to duration of treatment into :

A:- Twenty (20) children for those who received the treatment for six weeks duration, then depending on number of OPV doses received by children before treatment with N.S oil they were subdivided into five subgroups these are first ,second ,third ,fourth and fifth subgroup were assigned for children who had

one ,two ,three four and five OPV doses respectively. There are three children in the first, as well as in the second subgroup, four children in the third subgroup and five children in the fourth and so as in the fifth subgroups.

B:- Twenty –one(२१) children for those who were treated for three weeks duration , as in group A they were divided according to number of OPV doses into five subgroup. There are three children in the first as well as second subgroup and four, five and six children involved in the third ,fourth and fifth subgroup respectively .(Fig-१-)

The total IgG was also studied for this major group .

In the second major group ,thirty eight children were subjected to treatment at 0.३ ml/kg/day, as in first major group they were subdivided into .

A:-Eighteen(१८) children for those who had received the treatment for six weeks duration ,also this group subdivided into five subgroups according to number of OPV doses there are three children for each of the first ,second and third subgroup, where as there are four in the fourth and five in the fifth subgroups

B:- Twenty(२०) children for those who had received the treatment for three weeks duration ,each of the first ,second and third subgroup had three children and there are five and six children in fourth and fifth subgroup respectively. (Fig-१-)

۳.۳. Oil of Nigella sativa :

The oil of *Nigella sativa* has been obtained from the local medical supply centers in Baghdad, produced by Mousul Factory by the aid of supervisor Dr. Mohammed .A. Muhsin. As dose ۰.۶ ml /kg /day (Abdeen, *et.al.*, ۲۰۰۳).

۳.۴. Blood samples :

Blood samples were collected by the method of venipuncture. The area was first wiped with alcohol and left to dry. A disposable syringe of ۵ ml was used to aspirate about ۲-۳ ml of blood in plain tube then transferred to laboratory after labeled with the name and number of children. In the laboratory, the blood was left at room temperature for ۳۰ minutes till it clot then centrifuge at ۳۰۰۰ rpm for ۱۵ minutes. The sera of whole blood were aspirated and divided into ۰.۵ ml test tubes and storage at -۲۰°C till testing time. Each tube was used once to avoid repeated freezing and thawing. The sera before using were allowed to slaut at room temperature. All serum samples were heated at ۵۶°C for ۳۰ minutes to inactivate complement (Garvey *et.al.*, ۱۹۷۷).

۳.۵. Equipments and Tolls :

The equipments used during this work are :

The instrument	Company	Country
Autoclave	Webeco Gm bH	Germany
Automatic Pipettes	Organon Teknik	Belgium
Centrifuge	Damon IEC Division	USA
Water bath	Memmert	Germany
Disposable Syringe	Meheco	China
Disposable Tips	Nethler hinz	Germany
Disposable Plastic Tube	AFMA-Dispo	Germany
Sensitive Balance	Sartorius	U.K.
Oven	Memmert	Germany
Micro titration plate	Cookengineering Co-Alexandria	USA
Incubator	Memmert	Germany
Refrigerator		
Glass centrifuge tube	Stevilin	England
pH Meter	Philips	Holland
Filter Paper	Whatman, ۰.۲۲ Mm	Germany
Pasteur Pipette	Biomerieux	France

3.6. Solutions :

3.6.1. Normal Saline :

The solution was prepared by dissolving 0.8 g sodium chloride (NaCl; BDH Company; UK; MW=58.44) in 20 ml distilled water, then the volume was completed to 100 ml. The final concentration was 0.8%. The solution was then sterilized by autoclaving (121°C / 10 bar for 10 minutes. This solution was used for titration purposes.

3.6.2. Tannic Acid Solution :

The solution was prepared by dissolving 0.5 g tannic acid powder ($C_{14}H_9O_7$; BDH company; MW=339.12) in 20 ml distilled water, then the volume was completed to 100 ml with distilled water to obtain a solution with concentration of 0.5%, used to tan RBCs, i.e. to expose the Ags found on sheep erythrocyte surfaces (Garvey *et.al.*, 1977).

3.6.3. Citric Acid Solution

The solution was prepared by dissolving 10 citric acid Powder in 20 ml distilled water, then the volume was completed to 100 ml. The final concentration was 0.10%.

3.6.4. Alsever's Solution :

Alsever's solution is an isotonic solution, anticoagulant blood preserving solution that permits the storage of whole blood refrigeration temperature for about ten weeks (Talib, 1996). The solution was prepared by dissolving 24.6 g glucose (BDH company); 9.6 gm tri-sodium citrate (BDH company) and

0.4 g sodium chloride (BDH company) in 100 ml distilled water; the pH was then adjusted to 6.1 with 10% citric acid and filtered by using a 0.22 Mm pore's diameter membrane filter using micro filtration unit.

3.7. Reagents :

3.7.1. Prepared reagents: Preparation of tanned erythrocytes.

Sheep blood (10 ml) was obtained from the animal in a sterile condition, and then mixed with equal volume from Alsever's solution. The mixture kept at 4°C then from this mixture, 3 ml taken in a sterile centrifuge tube and centrifuged at 2000 rpm for 5 minutes. By using sterile Pasteur's pipette, the supernatant was discarded and the deposit was resuspended in 10 ml normal saline and centrifuged at 2000 rpm for 5 minutes. The supernatant was discarded and the deposit was resuspended in ten ml normal saline and mixed thoroughly.

From this mixture, three ml were taken in sterile centrifuge tube which contains three ml of 0.5% tannic acid solution mixed and placed in the water bath at 37°C for 10 minutes. The centrifugation was carried out at 2000 rpm for five minutes. The supernatant was discarded and to the precipitate three ml of normal saline were added and gently mixed.

3.7.2. **Ready made reagents:** Single radial immunodiffusion (SRID) test kits . Kallested endplate (SRID) test kits were used

for the quantitative determination of human immunoglobulin IgG in human serum (Sanofi diagnostic pasture ,USA)

3.8. Laboratory Investigaion :

3.8.1. Passive Haemagglutination Test (PHAT) :

According to the modified method of Garvey *et.al.*, (1977), PHAT was used to determine the level of immunity against polio in vaccinated or unvaccinated children , with or without Nigella sativa oil.

Determination of antibody level in children's sera:

Tanned sheep erythrocyte (3 ml) was mixed with 1 ml of polio vaccine and left at room temperature for about 10 minutes. It was then centrifuged at 2000 rpm for five minutes, the supernatant was discarded, and the deposit was re-suspended in 3 ml normal saline. Then centrifugation was done at 2000 rpm for five minutes the supernatant was discarded and the deposit was re-suspended in 3 ml normal saline and mixed.

Amicrotitration plate was used to estimate the level of antibodies in children's sera according to Garvey *et.al.*, (1977).

The procedure was carried out as follows:

1. Fifty μ l of normal saline was added in each well of plate (12 wells).
2. Ten μ l of children's sera was added to 90 μ l of normal saline in a sterile test tube and mixed well.

٣. Fifty μl of diluted children's sera (١:١٠) was added to the first well and mixed. Then double folds dilutions were prepared by transferring fifty μl from the first well to the second well, mixed well and fifty μl out of it was transferred to the third well and so on. From the eleventh well, fifty μl was discarded. The serial dilution was thus obtained from the first well till the eleventh one; ١:٢٠, ١:٤٠, ١:٨٠, ١:١٦٠, ١:٣٢٠, ١:٦٤٠, ١:١٢٨٠, ١:٢٥٦٠, ١:٥١٢٠, ١:١٠٢٤٠, and ١:٢٠٤٨٠ accordingly.
٤. The twelfth well contains fifty μl of tanned sheep erythrocyte covered with the polio vaccine was added (the last well represented the negative control well, which was not taking the presence of children's sera.
٥. The micro titration plates were shaken gently for ٣ minutes and then covered and incubated at ٣٧°C for ٣٤ hours. Then, the presence or absence of haemagglutination was recorded. PHAT titer represented the last dilution that gave a positive result.

٣.٨.٢. Single Radial ImmunoDiffusion (SRID) Test :

To estimate the (IgG) level between children who received N.S oil and children who did not ,SRID test kits (Sanofi kits)were used as in Mancini *et.al.*, ١٩٦٥ .A linear relationship exists between the Ag concentration and the

corresponding squared immune precipitin ring diameter that formed in an Ab gel system .

The test procedure was carried out as follows :

Five μ l serum from each individual was dispensed into wells of the plate containing agarose gel mixed with amonospecific antiserum .The plate was then covered and incubated at room temperature on a level surface for 24 hours for IgG estimation .The sample was diffused a radically through the gel and the Ag form a precipitating ring with the monospecific antiserum .The immuno –precipitation ring diameter was measured by the optical reader and the relevant concentration corresponding to the precipitates ring diameter was calculated from the conversion table provided with the kit.

3. 9. Statistical Methods

We used the (Mode) for study and analysis of data (Anti polio Antibody titers) for sampled children who were treated or not with N.S oil , so as the Range.

The Mean had been used to compare the results of total IgG for children who were treated with N.S oil with other not treated .

CHAPTER FOUR

RESULTS AND DISCUSSION

CHAPTER FOUR

RESULTS AND DISCUSSION

4.1. Assessment of Children Immunity against Poliovirus

The relationship between the number of OPV doses received by children and the anti - polio antibodies titers (APAbTs) have been shown in Fig (4). For unvaccinated children, seventy-five percent (75%) have 1:20 APAbTs against polio. The blood samples have been aspirated immediately after birth from umbilical cord and this indicates transplacental maternal antibodies (Ananthakrishman *et.al.*, 1988; Onorato *et.al.*, 1988). The other twenty-five percent (25%) of unvaccinated children have 1:40 APAbTs titer and all of them are of older ages. That may be due to contact with polio virus (vaccine-associated or wild virus) from others. For children who had one OPV dose, seventy-five(75%) percent of them have APAbTs of 1:40, the other twenty five(25%) percent of children had APATs of 1:80. For children who received two and three OPV doses, the APATs are similar, where seventy five percent of them have 1:80 APAbTs titer and other twenty five percent of them have APAbTs titer of 1:320. As for the children who received four and five OPV doses, the APAbTs are nearly similar where fifty four percent (54%) of them have APAbTs titer of 1:80 and

almost eight percent (8%) have 1:320. On the other hand, for the children who received four OPV doses, twenty eight percent (28%) have 1:160 and ten percent (10%) have 1:80; whereas for children who received five OPV doses, sixteen percent (16%) have 1:160 and twenty percent (20%) of them have a titer of 1:80.

From the findings above, there is a clear relationship between the number of OPV doses and the APAbTs titer, for the unvaccinated children have the lowest APAbTs titer. The APAbTs titers increase with subsequent OPV doses to reach a steady level of 1:80 after the second and third OPV doses, and remain relatively stable in the fourth and fifth OPV doses with slight variability that consist, with (Behrman *et.al.*, 2000, 2004).




Figure (2) :The Relation between the Immune Level against Polio virus and Number of OPV received by Children

The modes of anti-polio antibodies titers according to the number of OPV doses received by children (\mathcal{M} s) are represented in (Fig 3) independent of age, which also account for more than fifty four percent (54%) of the APAbTs titer of the corresponding OPV dose. These titers are $1:20$ for unvaccinated children, $1:40$ for children who received only one OPV dose, and $1:80$ for children who did two, three, four and five OPV doses. For unvaccinated children, this \mathcal{M} of antibody titer ($1:20$) reflects a transplacental passage of maternal antibodies during fetal life, which in turn reflects maternal serum level of polio antibodies. This, however, consists with (Ananthakrishnan, *et.al.*, 1988; Onorato *et.al.*, 1988). As for children who received only one OPV dose, this \mathcal{M} of APAbTs titer represents the primary response to a vaccine antigen. It consists with (Behrman *et.al.*, 2000, 2004). The antibodies titer achieve the highest level after the second OPV dose and remain constant with subsequent OPV doses; whereas the heightened humoral or cell mediated responses are elicited by a second exposure to the same T-dependant antigen the secondary responses occur rapidly, usually four –five days (Behrman *et.al.* 2000; 2004). The persistence of a stable APAbTs titer after a second OPV dose might be attributed to the repeated stimulation of immune system (memory cells) by the same antigen (vaccine).




Figure (٣) The titers of APAbTs according to the number of OPV Doses .

The level of (APAbTs) according to the age of children under study and independent the number of OPV doses has been evaluated in Fig (٤). The children have been divided into four groups as follows :

١. The first group, represents the neonatal period (less than one month old children). In this group, the children under study have APAbTs of ١:٢٠ and all of them have been investigated immediately after birth, as discussed

previously. So, the lowest level of antibody titer for children less than five years old occurs during this period.

٢. The second group of children are one month to one year old of age (infants period). The Range (**R**) of APAbTs is ١:٤٠ - ١:٣٢٠. Fifty two percent of the children have APAbTs equal to or less than, ١:٨٠ and, the other children have a titer of equal to, or more than, ١:١٦٠.
٣. The third group of children are one to ٣ years old (toddler age). **R** is ١:٤٠ - ١:٣٢٠, and Fifty six percent have APAbTs equal to or less than, ١:٨٠ and the rest have a titer equal to, or more than, ١:١٦٠.
٤. The fourth group are three to five years old (preschool age), **R** is ١:٤٠ - ١:١٦٠, ٢٢% have APAbTs of ١:٤٠, ٦٦% had ١:٨٠ and ١١% had APATs of ١:١٦٠.

The **R** for children younger than three years old (apart from neonatal period) is ١:٤٠ - ١:٣٢٠, whereas the **R** for older age is ١:٤٠ - ١:١٦٠. Higher percentage of children who are younger than three years old had higher antibodies titer ($\geq ١:١٦٠$) in comparison to older age. This might be due to repeated stimulation of the immune system by regular OPV doses through EPI applied in Iraq. The APAbTs titer for children older than three years old is nearly maintained at a stable titer (١:٨٠), which might be due to infrequent stimulation of the immune system by National immunization days (NIDs) administered annually at spring and fall seasons.




Figure (ε): Anti Polio Antibody Titers according to age independent the number of OPV Received by the child.

4.2. Evaluation of Nigella Sativa Oil effects on Specific Humoral Immune Response against Poliovirus in Children

The effect of N.S oil on specific humoral IR to polio has been studied , 0.7 ml/Kg /day in two divided doses for three and six weeks duration were used . There are two groups of children and each group is subdivided into five subgroups depending on the number of OPV doses received by children fig.(1) The M_s are used to make a comparison between the children taking N.S oil and the others who had not taken the oil . The M_s are also similarly compared between the children in different subgroups in Table (2).

The M_s for children who have not taken N.S oil (Fig 2) have been used as standard for comparison with M_s of matched children in the first, second and third subgroups. But the M_s of the same children before and after taking N.S oil have been used for comparison in the fourth and fifth subgroups.

1-The first group for children who had taken the prescribed dose (0.7 ml/Kg /day) for a six- week duration. In the first subgroup that represents the children who had only one OPV dose, the M is 1:80 after taken the oil ,whereas the M in this subgroup for the children who had not taken N.S oil is 1:40. In the second subgroup that represents children who had two OPV doses, the M is 1:160 after taken N.S oil , whereas M in this subgroup for the children who had not taken N.S oil is 1:80. The

third subgroup that represents the children who had three OPV doses ,the \mathcal{M} is $1:32$ after taken N.S oil ,whereas \mathcal{M} in this subgroup for children who had not taken N.S oil is $1:8$. In the fourth and fifth subgroups that represent the children who had four and five OPV doses respectively ,the $\mathcal{M}s$, before taking N.S oil were $1:8$ for each subgroup, and had changed into $1:32$ after taken the oil .

2-The second group for children who had taken the prescribed dose (0.7 ml/Kg /day) for a three- week duration. In the first and second subgroups that represent the children who had one and two OPV doses respectively, the $\mathcal{M}s$ after taken the oil, are $1:4$ for the first and $1:8$ for the second subgroups, which is similar to the $\mathcal{M}s$ for the children who had not taken N.S oil. In the third subgroup that represents the children who had three OPV doses ,the \mathcal{M} after taken N.S oil is $1:16$, whereas the \mathcal{M} for the children who had not taken N.S oil and received three OPV doses is $1:8$. In the fourth and fifth subgroups that represent the children who had four and five OPV doses respectively, the $\mathcal{M}s$ before taking N.S oil, are $1:8$, and had changed to $1:32$ after taken N.S oil as prescribed in dose and duration. The total of both first and second groups is collected and restudied regardless of the duration by which the prescribed dose (0.7 ml/Kg /day) is administered. The results in $\mathcal{M}s$ after having taken the N.S oil are similar to those in the first group.

From the results above, the positive role of N.S oil in the enhancement of specific IR to polio appears clearly and this enhancement is effected by the duration through which the N.S oil is given. The number of OPV doses received by children before taking N.S oil have significant effects on the induced IR. When they have taken (0.7 ml/Kg /day) for a six- week duration, the $\mathcal{M}s$ increase one fold for the children who had one and two OPV doses, and increase two folds for the others who had three or more OPV doses, whereas for children who had taken 0.7 ml/Kg /day for a three week duration, the $\mathcal{M}s$ have not changed for the children who had one and two OPV doses, but increased one fold for the children who had three OPV doses, and two folds for others who had four or more OPV doses. So, in the fixed dose of N.S oil, the more duration and OPV doses, the better IR against polio and vice versa. Although there is no similar study in which the N.S is used to enhance the IR specifically against polio, there are few studies by which the N.S is used to enhance general immunity in general (Cindy, 2000); (El-Kadi and Qandil, 2004; Meral *et.al.*, 2002 and Sanamin, 2004). All these studies explain the effect of N.S oil and might be related to the increase of production of antibodies, bone marrow cells and B-cells as well as the increase of the number of memory cells.

Table (3): Modes of APAbTs according to no. of OPV doses before and after 0.7 ml/Kg /day of NS oil

N.S Oil Dose (ml/Kg/day)	Duration (wks)	Total No.	Children received one OPV doses			Children received two OPV doses			Children received three OPV doses			Children received four OPV doses			Children received five OPV doses		
			No. of children	Mode without NS oil	Mode with NS oil	No. of children	Mode without NS oil	Mode with NS oil	No. of children	Mode without NS oil	Mode with NS oil	No. of children	Mode without NS oil	Mode with NS oil	No. of children	Mode without NS oil	Mode with NS oil
0.7	6	20	3	1:40	1:80	3	1:80	1:160	4	1:80	1:320	0	1:80	1:320	0	1:80	1:320
	3	21	3	1:40	1:40	3	1:80	1:80	4	1:80	1:160	0	1:80	1:320	6	1:80	1:320
Total no. of 0.7 ml		41	6	1:40	1:80	6	1:80	1:160	8	1:80	1:320	10	1:80	1:320	11	1:80	1:320

In Fig (°) there are three curves of $\mathcal{M}s$: two of them are for the children taking 0.7 ml/Kg /day of N.S oil for three- and six-week durations, the other curve for the children who have not taken N.S oil. The lower curve that represents the $\mathcal{M}s$ of children who have not taken N.S oil as in Fig (✓) and considered as standard to compare for other two curves, this curve starts to rise from a titer 1:20 to 1:40, then to 1:80 for unvaccinated, who received one and two OPV doses respectively, then the curve keeps stable at a level of 1:80 for further OPV doses (three or more).

In the second curve that represents the $\mathcal{M}s$ of children who have taken the prescribed dose for a three week duration, the curve rises gradually from a titer of 1:40 for the children who had only one OPV dose to 1:80 for those who had two OPV doses, to 1:160 for those who had three OPV doses then reaches 1:320 for those who had four OPV doses and persist at this level for further doses.

In the third (the upper) curve which represents $\mathcal{M}s$ of the children who had taken the prescribed dose (0.7 ml/Kg /day) for a six week duration, the curve rises from 1:80 for the children who had one OPV dose to 1:160 for those who had two OPV doses, then reaches 1:320 for those who had three OPV doses and persists at this level for further OPV doses.

From the three curves above, the undoubted effects of N.S on the enhancement of IR appear clearly. The magnitude of

the immune response also correlates well with the number of OPV doses and durations. This correlation might be related to the immaturity of the immune system during the first few months of life during which the child receives 2-3 OPV doses (Behrman *et.al*, 2000, 2004), whereas the correlation with duration might be due to prolonged stimulation of memory cells or other B-cells to achieve higher Abs titer.




Fig (°): Correlation between number of OPV doses and Modes of APAbTs at 0.1ml/kg/day of N.S oil.

The effects of N.S oil when using 0.5 ml/kg/ /day for three and six week durations (which is the half dose used in Table -3-) on specific immune response to polio have been studied in Table(4) The same statistical way applied in Table (3)has been used :

1- The first group, for children who had taken the prescribed dose for a six- week duration. The M_s without N.S oil are $1:40$ for the children who had one OPV dose and $1:80$ for those who had two or more OPV doses, and increased to $1:80$ for the children who had one OPV dose and $1:160$ for the children who had two or more OPV doses after taken N.S oil as described in dose and duration .

2- The second group, for children who had taken the prescribed dose of N.S oil for a three- week duration. For the first, second, and third subgroups the M_s are $1:40$, $1:80$ and $1:80$ respectively after taken the prescribed N.S oil. That is similar to M_s of children who had not taken N.S oil and had similar OPV doses. In the fourth and fifth subgroups, the M_s for the children who had taken N.S.oil are $1:80$ for each subgroup that change to $1:160$ after they were taken (0.5 ml/Kg /day) of N.S oil for a three- week duration.

As in Table (3), the total of both first and second groups is collected and restudied regardless of the duration. The results in M_s after having taken the N.S oil are similar to those in the first group.

From the results above, although we have used half the dose of N.S oil used in Table (3) in three- and six- week durations, there is still a positive role in the enhancement of specific humeral IR. This effect correlates with the number of OPV doses received by children before having taken N.S oil and duration through which we had administered the dose of N.S oil, whereas in the children who had taken 0.3 ml/Kg /day for a six week duration, the $\mathcal{M}s$ increased in the children who had one, two, three, four and five OPV doses by one fold as compared to those who had not taken N.S oil. When taking the same dose (0.3 ml/Kg /day) of N.S oil for half the duration (3 week), there are no changes in $\mathcal{M}s$ for the children who had one, two and three OPV doses, but there is an increase in $\mathcal{M}s$ by one fold for those who had four and five OPV doses.

In comparison with Table (3), there is a good relationship between the dose of N.S oil received by the children and the induced APAbTs. The $\mathcal{M}s$ after having taken a full dose (0.6 ml/Kg /day) regardless of the duration are 1:80, 1:160, 1:320, 1:320 and 1:320 for the children who had one, two, three, four and five OPV doses respectively, whereas the $\mathcal{M}s$ after having taken half the dose (0.3 ml/Kg /day) regardless of the duration are 1:80, 1:160, 1:160, 1:160 and 1:160 for the children who had one, two, three four and five OPV doses respectively.

Table (ε): Modes of APAbTs according to number of OPV Doses before and after 0.3 ml/Kg /day of NS Oil

N.S Oil Dose ml/Kg /day	Duration (wks)	Total no.	Children received one OPV dose			Children received two OPV doses			Children received three OPV dose			Children received four OPV dose			Children received five OPV dose		
			No. of children	Mode without NS oil	Mode with NS oil	No. of children	Mode without NS oil	Mode with NS oil	No. of children	Mode without NS oil	Mode with NS oil	No. of children	Mode without NS oil	Mode with NS oil	No. of children	Mode without NS oil	Mode with NS oil
0.3 ml /Kg /day	6	18	3	1:40	1:80	3	1:80	1:160	3	1:80	1:160	4	1:80	1:160	0	1:80	1:160
	3	20	3	1:40	1:40	3	1:80	1:80	3	1:80	1:80	0	1:80	1:160	6	1:80	1:160
Total of 0.3 ml		38	6	1:40	1:80	6	1:80	1:160	6	1:80	1:160	4	1:80	1:160	6	1:80	1:160

In Fig (٦) there are three curves of $\mathcal{M}s$: two of them are for the children who had taken ٠.٣ ml/Kg /day of N.S oil for six -and three- week durations; and the other curve is for the children who had not taken N.S oil. The lower curve that represents the $\mathcal{M}s$ of children who had not taken N.S oil is discussed previously in Fig (٥).

In the second curve that represents the $\mathcal{M}s$ for the children who had taken the N.S oil for a three week duration, the curve is similar to the first one (standard) for children who had one, two and three OPV doses, then rises to ١:١٦٠ for those who had four and five OPV doses.

The $\mathcal{M}s$ for the children who had taken the prescribed dose for a six -week duration are represented in the third curve (upper). The curve rises from ١:٨٠ for the children had one OPV dose to ١:١٦٠ for those who had two OPV doses, then remains stable at this titer for further OPV doses.

From the results above and in comparison with Fig (٥),it appears that in a fixed duration, the more N.S dose and more OPV doses produced, the better humoral IR against polio and vice versa. We have also noted that ٠.٦ ml/Kg /day of N.S oil for a six- week duration is considered the best dose(Abdeen *et.al*, ٢٠٠٣) and optimal time to produce the best enhancement of APAbTs.




Fig (٦): Correlation between number of OPV doses and Modes of APAbTs at ٠.٣ml/kg/day of N.S oil.

The magnitude of immune response induced by using 0.7 ml/Kg /day was evaluated in Table(9) and figures (10, 11 and 12) for the children who had four and five OPV doses (the same children were evaluated in the fourth and the fifth subgroups in Table-3-). Characteristically, there is no recent polio vaccination for this group of children. Ten children had been chosen as a control group.

There are ten children who had taken the prescribed oil for a six week duration; eight out of them (80%) have an increase in their APAbTs, and six of whom (60%) for two folds and two (20%) for one fold. The other two children (20%) had no change in their APAbTs.

On the other hand, there are eleven children who had taken the prescribed oil for a three week duration; eight (72%) out of them have their APAbTs increased, five (54%) for two folds and three (36%) for one. The other three children (27%) had no change in APAbTs. When the duration of taking the prescribed oil is excluded and the total children re-evaluated, there are sixteen (76%) whose APAbTs have increased; eleven (68%) by two folds, and five (32%) by one. There are also five children (23%) who had no change in their APAbTs.

For the control, group the basal level of APAbTs has been assessed, after three and six week durations. Two children (20%) had one fold rise in their APAbTs after six weeks, one of them has the APAbTs increase during the first three weeks.

From the results above, the magnitude of IR appears correlated well with the duration of N.S oil ,where the longer duration (six weeks) proves better than the shorter one (three weeks). This might be due to the prolonged stimulation of memory cells or other B-cells that result in higher Abs titers.

There are no changes in APAbTs for (۲۰٪)and (۲۷٪)of children who received N.S oil for six and three weeks respectively. This might be due to ecological, genetic, and nutritional factors, sub clinical illness or other causes.

The increase in APAbTs in few children in the control group might be due to contact with polio virus from other (vaccine related virus or wild virus) during this period of follow up, although a real attempt has been made to prevent contact with newly vaccinated children .

Table (°): The Magnitude of APAbTs after Taking 0.6 ml/kg /day from N.S Oil.

Dose ml/Kg /day	Duration (wks)	Total no. of children	Total no. of children who show increment	%	No. of children had one fold increment	No. of children had two fold increment	No change in titer	%
0.6	6	10	8	80	2	6	2	20
	3	11	8	72	3	0	3	27.2
Total of 0.6 ml		21	16	76	0	11	0	24
Control for 6 wks duration		10	2	20	2	-	8	80
Control for 3 wks duration		10	1	10	1	-	9	90




Figure (∇): The Magnitude of Immune Response with 0.6 ml/Kg /day for a six- week Duration of N.S Oil Treatment.




Figure (∧): The Magnitude of Immune Response with 0.6 ml/Kg /day for a three- week Duration of N.S Oil treatment.




Figure (9): The Magnitude of Immune Response with 0.6 ml/Kg /day of N.S Oil Regardless the Duration.

The magnitude of the immune response induced by using 0.3 ml/Kg /day was evaluated in Table(6) and Figs (10,11) and 12) for the children who had four and five OPV doses (the same children evaluated in fourth and the fifth subgroups in Table(8) This group of children had no recent polio vaccination. The same control group enrolled in Table (9) has been considered. There are nine children who had taken the prescribed oil for a six week duration : six out of them (66%) had an increase in APAbTs ,two children (22%) had two folds, and four (44%) had one fold increment. The other three children (33%) had no change in their APAbTs .

On the other hand, there are eleven children who had taken the prescribed oil for a three week duration: five (45%) of

them had their APAbTs increased, one (12.5%) by two folds and four (50%) by one fold. The other six children (75%) had no change in APAbTs. When the duration of taking the prescribed oil was excluded and the total children re-evaluated, there are eleven (75%) whose APAbTs had increased, three (21%) by two folds, and eight (56%) by one fold. There are nine children (60%) who had no change in their APAbTs.

In comparison with Table (5), the important role of the dose of N.S oil is clear, where seventy-six (86.7%) percent of the total children taking 0.6 ml/Kg /day regardless of the duration had an increase in their APAbTs as compared with fifty five percent (70%) for the children who had taken half the dose as in Table (6). Similarly in respect the magnitude of APATs where fifty two percent (69.3%) of the total children who took the full dose (0.6 ml/Kg b.w/day) regardless the of the duration have two folds increment in their APAbTs in comparison with fifteen percent (20%) of children who did not taken half the dose.

Finally, although the duration has an important effect on the magnitude of APATs, the dose of N.S oil is more important; where forty-five (60%) of the children who had taken the full dose (0.6 ml /Kg / day) in half the duration (3 weeks) have two folds increment in comparison with only twenty-two percent (29.3%) of children who had taken the half dose (0.3 ml/Kg /day) in full duration (6 weeks).

Table 6: The Magnitude of APAbTs after taking 0.3 ml/kg/day of N.S Oil for three-and six- week Duration

Dose (ml/Kg /day)	Duration (weeks)	Total no. of children	Total no. of children who show increment	%	No. of children had one fold increment	No. of children had two fold increment	no change in titer	%
0.3 ml	6	9	6	66.6	4	2	3	33.3
	3	11	0	0	0	1	6	0%
Total of 0.3 ml		20	11	55	8	3	9	40%
Control for 6 week duration		10	2	20	2	-	8	20%
Control for 3 week duration		10	1	10	1	-	9	10%




Figure (10) : The Magnitude of Immune Response with 0.3 ml /Kg /day) for a six week- Duration of N.S Oil Treatment.




Figure (11) : The Magnitude of Immune Response with 0.3 ml /Kg /day for a three- week Duration of N.S oil Treatment.




Figure (١٢) : The Magnitude of Immune Response against polio with ٠.٣ ml /Kg /day of N.S Oil Regardless the Duration.

٤.٣. Assessment of N.S Oil Effects on Total Immunoglobulin –class G

The effect of N.S oil on humoral immunity by measuring the total IgG level has been studied in Table (٧) for the children who had taken ٠.٦ ml /Kg /day) of N.S oil for three- or six-week durations.

The range **R** of total IgG before treatment is ٢٨٠-١١٣٣.٧ mg/dL and the mean is ٤٨٨.٣ mg/dL, whereas for the children treated by N.S oil for a three week duration, the **R** of total IgG is ٤١٢.٦-١٣٣٩.٥ mg/dL and the mean is ٩٨٦.٦mg/dL

For the children treated with ٠.٦ ml/ Kg /day of N.S oil for a six week durations the **R** of total IgG is ٤٣٨.٤-١٤٠٨.٥ mg/L and the mean is ١٠٢٥.٣ mg/dL.

From the results above, the enhancing role of NS oil on general humeral immunity appears clearly and this effect correlates with the duration of treatment with N.S oil. This effect might be related to increase the production of antibodies, bone marrow cells and B-cells. It may also be due to increase in the number of memory cells. This consists with what was reported by Cindy, ٢٠٠٠; EI -Kadi and Qundil ٢٠٠٤ and Meral et al, ٢٠٠٣;Sanamin,٢٠٠٤).

Table (V) : N.S Oil Effect on Total IgG Level

Group	Range of total IgG level (mg/dL)	Mean of total IgG level (mg/dL)
Before N.S oil	۲۸۰-۱۱۳۳.۷	۴۸۸.۳
After ۳- week treatment with ۰.۶ ml /Kg /day of N.S oil	۴۱۲-۱۳۳۹.۰	۹۸۶.۶
After ۶- week treatment with ۰.۶ ml /Kg /day of N.S oil	۴۳۸.۴-۱۴۰۸.۰	۱۰۲۰.۳

CONCLUSION

- ١-There is a clear relationship between the number of OPV doses and the specific antibodies titers against polio , where the lowest APAbTs for unvaccinated children is ١:٢٠ and then the APAbTs increases with subsequent OPV doses.

- ٢-There is no difference in specific antibodies titers against polio for children who had two or three OPV doses.

- ٣-There is some correlation between the age of children and the level of APATs ; the lowest is during neonatal period and the range of APATs for children younger than three years apart from neonatal period is ١:٤٠ - ١:٣٢٠ , whereas that of older children is ١:٤٠ - ١: ١٦٠ .

- ٤-N.S oil had important positive role in the enhancement of specific humoral immunity against polio on both total number of responses children and the magnitude of this immune response, and this positive role depends on :

a-Dose of N.S oil :(0.6 ml/kg /day)is the best dose that had achieved the best results in a fixed duration as compared with lower dose (0.3 ml/kg /day) that yeilds the lowest result .

b- Duration of treatment : A course of a six- week duration in a fixed dose of N.S oil produces a higher immune response in comparim with the shorter duration(3 weeks).

c-Number of OPV doses received by children befor N.S oil treatment :The children who have four or more OPV doses had better immune responce in a fixed dose and duration in comparison with the children who have the lowest OPV doses.

d-N.S oil has a positive role in increasing total immunoglobine – class G (IgG) for children, and this role also correlates with Durtion of treatment.

RECOMMENDATIONS

In accordance with the results of this study ,and to ensure an increase in childrens specific immune responses against Polio that have a scheduled vaccination programme, we recommended that:

1-The use of N.S oil becomes a part of daily meals for children by adding the oil to milk ,fruit juice or other types of foods.The recommended dose is 0.7ml/kg/day .

2-The use of N.S oil as shown be encouraged a part of processed food.

3-Children are encourage to have N.S oil when they receive OPV doses.

4-Further reasearch works in this fields against other viral and bacterial infectious disease are encouraged as part of the effort to control these disease.




Figure 1 : The Division of Children

References

References

- Abdeen ,A .M .; Fouad ,S .; Hessian ,S .H .; Shaheen ,H .I .;
Abdeen ,S .H ., ٢٠٠٣, using of Nigella Sativa in
children ,J Egypt. Ger .Soc .zool .vol ٢٠ (A) ١٨٩ -٢٠٨
- AdimA. ١٩٨٥, Synthetic Adjuvants, modern concepts in
Immunology vol ١. Paris, University of Paris-udOrsay,
Institute of Biochemistry, .
- Ali –AL Rawi :Ph D ١٩٨٨, Nigella sativa ,Medicinal Plant of
Iraq ,٦٩,
.
- Ali NM. ١٩٩٧, Biochemical study for the seeds of Nigella sativa
(Ranunculaceae). A thesis submitted to the college of
science, university of Basrah, in partial fulfillment of
requirements for the degree of Master of Science of
chemistry..
- Al-Kaisey MT, Baqir AW and Al-Ani AH. ٢٠٠٢. Chemical
composition of the black cumin (Nigella sativa) seeds
growing in Iraq. A specialised symposium on the
researches of Nigella sativa which was held in the
Leader's College of Pharmacy on ١٥th of May
Baghdad.
- AreiJ. Zukerman ,jaugu .E. Bauntvala and Jhon R. Pattison
(٢٠٠٠). Poliovirus infection . ٤th edition .principles of
clinical virology .Great Britain by book craft
(Bath) Ltd ,midsomer norton somerret P. ٤٤٤-٤٤٥ .

Ananthakrishmans (١٩٨٨) .Poliovirus antibody titer in cord blood And its correlation with antenatal and Natal factors Indian . Pediatrics , ٢٥:١٠٣٣-١٠٣٩.

Badary OA, Al-Shabanah OA, Nagi MN, ١٩٩٩. Inhibition of benzo (a) pyrene-induced forestomach carcinogenesis in mice by thymoguinone. Eur-J-Cancer-Prev. Oct;٨(٥):٤٣٥-٤٤٠.

Baqir AW, Al-Ani AH and Al-Kaisey MT. ٢٠٠٢ Inhibitory action of Iraqi Nigella sativa seeds extraction against some pathogenic micro-organisms. A specialised symposium on the researchers of negilla sativa which was held in the Leader's College of Pharmacy on ١٥th of May. Baghdad.

Beal ,A.J. (١٩٩٠) :polio vaccines :Time for a change in immunization policy .Lancet.٣٣٥:٨٣٩-٨٤٢ .

Behrman ,Kliegman ,Jenson ,٢٠٠٠.Nelson Textbook of Pediatrics. Immunization practices Pp١٠٨٠-١٠٨٤.Enterovriuses Pp.٩٥٦-٩٦٠.

Behrman ,Kliegman ,Jenson ,٢٠٠٤.Nelson Textbook of Pediatrics. Immunization practices Pp.١١١٦-١١١٩.

Bottiger M ١٩٨٤, long term immunity following vaccination with killed poliovirus vaccine in Sweden a country with no circulating poliovirus . Rev Infect Dis ٦ (suppl ٢) : S٥٤٨ ,.

Brooks,G.F;J.S. Butel; and S.Morse(١٩٩٨).Jawets,Melninck and Adelbergs Medical microbiology,٢١st ed.,Appelton and Lang, California.

- Burits , M ; Bucar , F, ٢٠٠٠. Anti oxidant activity of Nigella Sativa essential oil .phytother .Res .١٤ (٥) : ٣٢٣ -٨ . .
- Cindy L.A.Jones , ٢٠٠٠, Herbal Aids for cancer Issue of Nutritionce news .
- Chakravarty N., ١٩٩٣. Inhibition of histamine release from mast cells by nigellone. Ann-Allergy. Mar;٧٠(٣):٢٣٧-٢٤٢.
- Christie ,A.B. (١٩٨٧) Infectious Diseas:Epidemiology and Clinical pratice ٤th edn, vo ١.٢.churchill livingstone, Edinburgh clements,G.B.,Galbraith,D.N.and Tylor, K.W.(١٩٩٥ a) Cocksackie B virus infection and onset of child hood diabetes.lancet,٣٤٦,٢٢١-٣.
- Dalakas MC ,Sever JL, ,Modden DL., ١٩٨٤.Late post poliomyelitis muscular atrophy ,:clinical ,virological and immunological studies .Rev Infect .Dis ٦(suppl٢) : S ٥٦٢ –S٥٦٧ , .
- DarjiA,GuzmanCA,GerstolB ١٩٩٧.Oral somatic trans gene vaccination using attenuated S.typhmuurium.Cell ٩١:٧٦٥-٧٧٥.
- Dowdle WR,Birmin gham ME, ١٩٩٧. The biological principle of Polio virus eradication . J, infect.Dis.;١٠(٥) :٢٠-٢٣.
- El-Hazmi M., Al-Fawaz I., Warsy A., ١٩٩٢. Piracetam for the treatment of sickle cell disease in children – a double blind test. Saudi Medical Journal.;١٩(١):٢٢-٢٧.
- El-Kadi and Kandil , ٢٠٠٤,Black seed, [http://www. The muslim women .com/her health/blak seed.htm](http://www.The-muslim-women.com/her-health/blak-seed.htm).

- El –Feki ,M.A. Radawan Z.A ., Abdel –Monaiam ,A.A. and Salah E . ,J , ١٩٩٧ ,J.Egypt .Ger .Soc . ٢٠٠١ . ٢٣ (A) ١٦١ -١٨٦
- Evans A.S.,(١٩٨٤).criteria of assessing accomplishment of poliomyelitis control.Rev.Inf.Dis.٦ (suppl.٢): S ٥٧١-٥٧٥.
- El-Tahir KE, Ashour MM and Al-Harbi MM. ١٩٩٣, The cardio vascular actions of the volatile oil of the black seed (Nigella sativa) in rats. Elucidation of the mechanism of action. Gen-pharmacol. Sep;٢٤(٥):١١٢٣-١١٣١.
- Expanded program on Immunization(١٩٩٣):The immunological Basis for immunization series .module ٦:Robertson S., poliomyelitis world health organization Documents whole EPI/٦EN/٩٣:١٢-٩٣
- Expanded programme on Immunization(١٩٩٥).Immunization Policy in : Global programme for vaccine and Immunization who/EPI/GEN/٩٥.٣:١٠-٢٠:Geneva, Size land, world health organization.
- Expanded program on Immunization (١٩٩٧). Information System. Global Summary August .Geneva, World Health Organization .
- Faden H ,DuffyL,Sun M ,Shuff C ,١٩٩٣ .Long-term immunity to poliovirus in children immunized with live attenuated and enhanced potency inactivated trivalent poliovirus vaccines Infect Dis ١٦٨:٤٥٢-٤٥٤,.
- Fortuin M,Maie N,Mendy M,١٩٩٥. Measls,polio and tetanus Toxoid antibody levels in Gambian children aged ٣to٤years following routine vaccination. trans soc. trop med Hyg. ٨٩: ٣٢٦-٣٢٩,.

Fulginiti VA, 1980. practical aspect of immunization practice. In Fulginiti VA (ed) . Immunization in clinical practice. Philadelphia JBLippincott, Pp 9-00.

Funkhouse AW, Wassilak SG, Orenstein WA. 1987 Estimated effect of delaying the recommended vaccination schedule for diphtheria and tetanus toxoids and pertussis vaccine. JAMA 207: 1341-1346,.

Gamble, D.R. (1984) Enteroviruses: polio-, echo- and coxsackie Viruses. In Topley and Wilson's principles of Bacteriology, Virology and Immunity, 14th, edn, vol, 2 (eds G. Wilson A. Miles and M.T. Parker) Pp 394-419. Edward Arnold, London

Garvey, J.S.; N.E. Cremer and D.H. Sussdorf (1977). Methods in Immunology, 3rd, 306-360. Addison-Wesley publishing company, Inc. Reading.

Geison, GL 1990. The private Science of Louis Pasteur. Princeton, NJ, Princeton University press, Ghendon Y. and Robertson S.E., (1994). Interrupting the transmission of wild polioviruses with Vaccines: Immunology consideration. Bal. WHO 72(6): 973-983.

Ghosheh OP, Houdi AA and Grooks PA., 1999. High performance liquid chromatographic analysis of the pharmacologically active quinones and related compounds in the oil of the black seeds. J-Pharm-Biomed-Anal. Apr; 19(5): 707-762.

Gilani, A.H.; Aziz, N.; Khurran, I M; Chandhary, K.S; Iqbal, A., JPak-med- Assoc. 2001 mar; 5(3): 110-20.

Grist NR, Bell EJ, 1984. Paralytic poliomyelitis and non-polio enterovirus studies in Scotland. Rev. Infect. Dis 6 (suppl 2): 5383, .

Gromieier ,M, Wimmer E , 1998. Mechanism of injury provoked Poliomyelitis .J.virology; 72 : 5056 -60 .

Hammed HA, Abid FM and Hamad AWR, 2002. Determination of mineral compositions of Iraqi Nigella sativa seeds by atomic absorption spectrophotometer. A specialized symposium on the researchers of Nigella sativa that was held in the Leader's College of Pharmacy on 10th of May . Baghdad. University .

Hanafy MS and Hatem ME, 1991. Studies on the anti-microbial activity of Nigella sativa seeds. J-Ethnopharmacol. Sep; 34(2-3): 270-278.

Harjulehto T., (1986) .Cnge nital malformation and oral polio Viruses vaccination during pregnancy lancet. 1: 771-772.

Harjulehto –Mervanla T , Arot ,HiilesmaaVK , .Oral polio Vaccination during pregnancy No increase in the Occurrence of malformation Am.J.Epidemiology. 13: 407-414, 1993.

Hinman A.R.Foege W.H., Dequadros C.A., PatriarcaP.A., Orenstein W.A., and Brink E.W., (1987). The case For global eradication of poliomyelitis .Bull of WHO . 56 : 830-84

Haq A., Abdulatif M., Lobo PI, Khabar KS, 1990. Nigella sativa: affect on human lymphocytes polymorphonuclear

leukocyte phagocytic activity. Immunopharmacology. Aug; 30(2): 147-150.

Hull HF, Ward NA, Hull BP, 1994. paralytic poliomyelitis: seasonal strategies, disappearing disease. Lancet 343: 1331-1337, .

Hyde, R.M. (2000). Immunology, 4th ed. The national medical series for independent study, lippincott Williams and Wilkins, USA.

Jawetz, Melnick Adelbrgs (1998). Picornaviruses (Enterovirus And Rinovirus group) in: Jawetz, Melnick and Adelbergs Medical Microbiology. 21st Edition. Middle East Edition Appelton and lange Pp: 444-451.

Jubelt B, Gallez, Hawkins G, Nava V/ano, Johnson RT, 1980. Pathogenesis of human polio virus infection in Mice. II. Age dependency of paralysis. J Neuro pathol. Exp. Neurol.; 39: 138-148.

Krugman R., (1998) Enteric viruses (History) Pediatrics, 81-83

Kanter M, Meral I, Ded S, Cemek M, Osbek H, Uggan I and Gunduz H.J, 2003. Veterinary Medicine A. volume 98, Issue 6 page 24, June.

Lieberman JM, Greenberg DP, Wong VK., 1990. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines pediatric 126: 18-20, .

Linder N, Yaron M, Handsher R, 1990. Early immunization with inactivated poliovirus vaccine in premature infants. *J. Pediatr.* 127:128-130,.

Mancini G, A.O. Carbonara and J.F. Heremans (1960) Immunological quantitation of antigens by single Radial immunodiffusion *Immunochemistry*, 2:230-204

Melnick J L., 1984. Enterovirus type 11 infection: A varied clinical pattern Sometimes mimicking paralytic poliomyelitis. *Rev. Infect Dis* (suppl 2): S387,.

Melnick J L, 1990. Enterovirus: polioviruses, coxsackie viruses, echoviruses, and newer enterovirus, In Fields BN, Kuip DM, Chanock RM, (eds). *New York Raven Press*, Pp 049-600.

Melnick J L. (1990) Enteroviruses : Polioviruses , Coxsackie Viruses , Echoviruses and Newer Enteroviruses: Field Virology 3rd edition Lippincott-Raven. Publisher . 600-712

Meral, I, Yener, Kaharaman , T; Met , N-N. J. A (10) : 093 -9 .
Vet -Med. A. Phsiol -Phthol -clin-me, 2001 Dec.
[midlin]

Minor P.D., Belle. J (1990). Picornaviridae (excluding Rhinoviruses) in Topley and wilsons principles of bacteriology , virology and immunity , 8th Edition vol . 4, London : Edward Arnold Pp 324-32-

Minor , P.D. (1996) poliovirus . In viral pathogenesis (eds N. Nathanson , R. Ahmed , F. Gonzalz -Scarano et al) Pp 000-074: Lippincott-Raven Philadelphia

- Modlin JF, Halsy NA, Thomas ML, 1997. Humoral and Mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine – Live attenuated oral poliovirus vaccine immunization schedules. *J Infect Dis* 170(suppl 1):S228-S234,.
- Morens DM, Pallansch MA, Moore M, 1991. Polioviruses and other enterovirus. In Belsh RB (ed). *Text book of Human virology* (2nd ed). St. Louis, Mosby, Pp 427-497.
- Morsi NM, Antimicrobial effect of crude extract of N.S on multiple Antibiotics-resistant bacteria, *Acta-microbial-pol.* 2000; 4, (1): 63-74 [Midlin]
- Munsat T.L. (1991) Poliomyelitis new problems with An old disease. *New England Journal of medicine* 324-1206.
- Muridin AD, Luhh, Murray MG, Wimmer E. poliovirus antigenic hybrids simultaneously expressing antigenic determinants from all three serotypes. *J Gen. virol* 73: 607-611, 1992.
- Ogra P.L. and Karzon D.T., (1971) formation and function of poliovirus antibody in different tissues progress In *medical virology*. 13: 106-193.
- Ogra P.L., 1984. Mucosal immune response to polio virus Vaccines in childhood. *Rev. Infect Dis.*; 6: 0361-0368.
- Onorato IM, Markowitz LE, Oxtoby MJ., 1988. Childhood Immunization, vaccine – preventable disease And infection with human immuno deficiency Virus. *pediatr. Infect. dis J.*; 7: 088-090.

Onorato IM , Modlin JF, McBean AM, 1991. Mucosal immunity induced by enhance potency in activated and oral polio vaccines J Infect Dis 163:1-6.

Orenstien WA ,Wassilak SGF ,DeFrest A, 1988. Sevoprevalence of poliovirus antibodies among Massachusetts School children (abstract 012) .In 88thInterscience conference on antimicrobial Agents chemotherapy. Washington, DC,American Society forMicrobiology , p198.

Parslow,T.G.(1991).The immune response .In: T. G. Parslow; D .P. Stittes; A. I .Terr and J. B. Immunology, 3ed, Pp.: 61-71.Mc Graw Hill Comp.,USA.

Patriaca P.A. Sutter R.W., Ootvogel P.M., (1997). outbreake of paralytic poliomyelitis 1976-1990.J.Inf.Dis. 170(suppl.1): S160-72 .

Racaniello V.R.,(1988) poliovirus neurovirulance in Maramorosch K., Murphy F.A.,Shatkin A.J. (ed) , Advances in virus research .Harcourt. Brace Jovanovich publisher,volume 34,Pp 217-246 .

Racaniello V.R poliovirus spreads from muscle to the Control nervous system by neural pathway . J Infect.Dis. 1992: 166: 747-752.

Ramsay ME , BegyNT, Chndi,BrownD. ,1994. Antibody response And viral excretion after live polio vaccine or a combined shodule of live and inactivated polio vaccines pediater. Infect .Dis .J.13:1117- 1121.

RiechmanL, ClarkM, WadmannH, WinterG. ,1988. Reshaping humanantibodies for therapy .Nature332:323-327.

Roitt ,I .and A .Robson (२०००) .Realy Essential Medical Immunology १st ed ., Blackwall Science ,U .K .

Roitt ,I .Jonathan ,B.David ,M., (२००१) ,vaccination ,१st ed . British library .

Robbins FC, १९८६.International Symposium on poliomyelitis control. Sumary and recommendation. Rev Infect Dis १(suppl २): S०९६.

Ryder R.W,Oxtopy M.J, Mrula M, १९९३. Safty and Immunogenicity of bacilli clamette- Guevin Diphthervie, tetanus pertussis and aral polio Vaccines in newborn type १.J Pediatier १२२: ६९१-१०३,

Sabin AB., १९८१, paralytic poliomyelitis: old dogmas nd new perspectives. Rev Infect Dis ३:०४३,.

Sabin AB. १९८०, Oral poliovirus vaccine: History of its development and use and current challenge to eliminate poliomyelitis from the world . J Infect.Dis १०१:४२०-४३६,

Salem M.L;Hossain,N.S, २०००.Protective effect of black seed oil from Nigella sativa ganist murin cytomegalovirus infection, J. Immunopharmacol . २२(९) १२९-४०.

SalisburgDM,RamsayME,WhiteJM,BrownDW., १९९१.polioradic ation in Surveillance implication for the United kingdom .J Infect Dis ११०(suppl १) :S१०६-S१०९.

Salk J , १९८४.One does immunization against paralytic poliomyelitis using non infectious vaccine.Rev Infect Dis १(suppl २): S४४४.

Samuel L. Katz, Aune A. Gershon and ete J. Hoter. (1998). Enteroviruses (history/: Harley Rotbat Krugmans. Infectious diseases of children. 10 Edition. United status of America , P81-85.

Sanamin , Nigella Sativa, an ancient egyptian cure, nature's healing Ways, 2004, <http://www.Sanat.ch/english/Nigella.htm>.

Shams Al-Deen A. 1410 هـ - 1990. التداوي بالاعشاب والنباتات قديم وحديث

Stanley A.P. & A.O. Walter, 1999. Vaccines . chapter 16 , Live attenuated poliovirus vaccines . 3 ed . edn . W . B . Sadars Company . P. 364 - 408 .

Strebel P.M., Sutter R.W., Coch .S.L., (1992). Epidemiology of Poliomyelitis in the united states , one decade after the last report case of indigenous wild virus associated disease . clin . Infect . Dis 14: 568-578.

Streble P.M., (1994) . Poliomyelitis in Romania , 1984-1992. Evidence of high risk of vaccine associated disease and reinteroduction of wild virus infection - Amer . J . Epidemiol. 140: 1111-24.

Sutter .R.W., Patriarca .P.A., Sulaiman A.M ., Pollansch M.A and zell E.R . (1992) . Attributable risk of DTP (diphtheria and tetanus toxins and pertusis vaccines) injection in provoking paralytic poliomyelitis during a large outbreak in Oman, J. inf . Dis. 165: 444-449 .

Sutter R W Pallansch MA , Sawyer LA , 1990. Deffining Surrogate serological tests with respect to predicting protective vaccine efficacy : polio virus vaccination . A nn NY Accdsci 704: 289-299.

Thomas MA (1984). Picornaviruses, poliovirus medical microbiology. 1st edition Great Britain by Robert Hartnoll Ltd. Bodmin, Cornwall.

Vernon A, Okwo B, Lubmaba N, Miaka MB. (1990). Paralytic poliomyelitis and HIV infection in Kinshasa. In Sixth International conference on AIDS; June 20-24; San Francisco, CA.

Wessels MR, Paoletti IC, Kasper DL (1990). Immunogenicity of animals to a poly-saccharide-protein conjugate vaccine against type III of group B streptococcus. J Clin Invest 86: 1428-1433.

Willms RS, Johnston SA, Riedy M. (1991). Introduction of foreign genes into tissues of living mice by DNA-coated micro-projectiles. Proc Natl Acad Sci USA 88: 2726-2730.

Worthen DR, Ghoshen OA, Crook PA. (1998). The in vitro anti-tumor activity of some crude and purified components of black seed (Nigella Sativa). Anticancer Res 18 (3A): 1027-32.

World Health Organization (1988). Assembly. Global eradication of poliomyelitis by the year 2000. Geneva, World Health Organization.

World Health Organization Expert Committee on Biological Standardization (1990). Requirements for poliomyelitis vaccine (oral) Technical Report Series No. 8.

World Health Organization . Expanded program on Immunization (1992) .poliomyelitis outbreak ,Bulgaria weekly Epidemiology .Res .67:3367 .

World Health Organization .United Nation children Fund .Geneva (1996) .vaccines used in the expanded program of immunization in : state of worlds vaccine and immunization WHO /GPV/96.04.

World Health Organization (1997) potency testing of live viral vaccines ;live oral poliomyelitis vaccine in :manual of laboratory methods for testing of vaccines used in the WHO expanded program of immunization :vaccine supple and quality .WHO /VSQ/97.04.Geneva

World Health Organization (1999) Report of the : fourth meeting of the global Commission for the Certification of the Eradication of poliomyelitis ,Department of vaccines and biological .WHO /V&B/99.31.

